carbamates and amprenavir

carbamates has been researched along with amprenavir in 433 studies

Research

Studies (433)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's89 (20.55)18.2507
2000's271 (62.59)29.6817
2010's67 (15.47)24.3611
2020's6 (1.39)2.80

Authors

AuthorsStudies
Livington, DJ; Painter, GR; Partaledis, JA; Pazhanisamy, S; Porter, DJ; Tung, RD1
Blair, EE; Cullinan, AB; Falcione, C; Futer, O; Maschera, B; Myers, RE; Partaledis, JA; Pazhanisamy, S; Tisdale, M; Yamaguchi, K1
Bilello, JA; Drusano, GL1
Cullinan, AB; Livingston, DJ; Margolin, N; Pazhanisamy, S; Rao, BG; Stuver, CM1
Blum, MR; Millard, J; Painter, G; Parry, N; Rooney, J; Sadler, BM; St Clair, MH; Tisdale, M1
Chang, SY; Singh, R; Taylor, LC1
Kim, EE; Murcko, MA; Rao, BG1
Garsky, VM; Kuo, LC; Schock, HB1
Blair, ED; Darby, G; Furfine, ES; Maschera, B; Myers, R; Palú, G; Tisdale, M; Wright, LL1
Bold, G; Capraro, HG; Goutte, G; Klimkait, T; Lazdins, JK; Mestan, J; Walker, MR1
Maggiora, GM; Mestres, J; Rohrer, DC1
Miertus, S; Nair, AC; Romeo, D; Tossi, A1
Livingston, DJ; Partaledis, JA; Pazhanisamy, S; Rao, BG1
Itoh, E; Shibata, N; Terashima, S1
Adkins, JC; Faulds, D1
Bridson, GW; Chaturvedi, PR; Decker, CJ; Laitinen, LM; Raybuck, SA; Tung, RD1
Bart, PA; Corpataux, JM; de Boer, RJ; Fleury, S; Gallant, S; Gillet, M; Glauser, MP; Graziosi, C; Knabenhans, C; Meuwly, JY; Meylan, P; Miedema, F; Otto, SA; Pantaleo, G; Rizzardi, GP; Schnyder, P; Soudeyns, H; Spreen, W; Welbon, CC; Wolthers, KC1
Bilello, JA; Bilello, PA; Bye, A; D'Argenio, DZ; Drusano, GL; McDowell, J; Sadler, B; Symonds, W1
Cammack, N; Chirn, GW; Craig, C; Dissanayeke, S; Duncan, IB; Gilbert, S; Moffatt, A; Race, E; Rose, J; Sheldon, J; Whittaker, L1
Boden, D; Markowitz, M1
Bawdon, RE1
Caliendo, AM; Currier, JS; D'Aquila, RT; DeGruttola, V; Eron, JJ; Frank, I; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, L; Sommadossi, JP; Tung, R1
Cassano, P; Clumeck, N; De Wit, S; Gerard, M; Hermans, P; Kabeya, K; O'Doherty, E1
Miller, SL1
Chittick, GE; Hanson, CD; Roskell, NS; Sadler, BM; Symonds, WT1
Baggett, TH; Gracia Jones, S1
Bart, PA; Corpataux, JM; Fleury, S; Knabenhans, C; Meuwly, JY; Meylan, PR; Munoz, M; Pantaleo, G; Rizzardi, P; Welbon, C; Yerly, S1
Brouwer, KR; Dennis, SW; Humphreys, JE; Jarrett, JL; Polli, JW; Studenberg, SD; Woolley, JL1
Berger, J; Li, Z; MacNaul, K; Moller, DE; Szalkowski, D; Zhang, B1
Temesgen, Z; Wright, AJ1
Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME1
Chittick, GE; Crouch, MA; Gouldin, W; Israel, DS; Lou, Y; Pastor, A; Polk, RE; Sadler, BM; Symonds, WT1
Gatell, J1
Bridgers, A; Coffin, M; Long, S; Polli, J; Roy, A; Vickers, A; Winnike, R; Yu, L1
Falloon, J; Kavlick, MF; LaFon, S; Lane, HC; Manion, DJ; Masur, H; Mitsuya, H; Piscitelli, S; Rogers, M; Sadler, B; Vogel, S; Yoshimura, K1
Anderson, C; Craik, CS; Jolly, DJ; Todd, S1
Heinrikson, RL; Tomasselli, AG1
Delvaux, M; Fosse, S; Gillotin, C; Lou, Y; Masliah, C; Petite, JP; Pillegand, B; Rautaureau, J; Sadler, BM; Stein, DS; Veronese, L1
Brophy, DF; Chittick, GE; Gillotin, C; Israel, DS; Lou, Y; Pastor, A; Polk, RE; Sadler, BM; Symonds, WT1
Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G1
Arnold, E; Das, K; Limoli, K; Parkin, NT; Petropoulos, CJ; Ziermann, R1
Gulick, R1
Currier, JS; D'Aquila, RT; Eron, JJ; Fiscus, SA; Gulick, RM; Lennox, JL; Murphy, RL; Rogers, MD; Smeaton, LM; Tung, R1
Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A1
Barone, C; Bilello, JA; Bye, A; D'Argenio, DZ; Drusano, GL; LaFon, S; Preston, SL; Prince, W; Rogers, M; Symonds, W1
Fung, HB; Hameed, R; Kirschenbaum, HL1
Beijnen, JH; Hoetelmans, RM; Sparidans, RW1
Daily, JP; Fahey, JM; Greenblatt, DJ; Perloff, MD; von Moltke, LL1
Black, J; Markland, W; Parsons, JD; Rao, BG; Tisdale, M; Tung, R; Zuchowski, L1
Jaillon, P; Poirier, JM; Radembino, N; Robidou, P1
Condra, JH; Emini, EA; Petropoulos, CJ; Schleif, WA; Shivaprakash, M; Ziermann, R1
Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A1
Duan, SX; Durol, AL; Greenblatt, DJ; von Moltke, LL1
Croom, DK; Furfine, ES; Lenhard, JM; Reynolds, DJ; Spaltenstein, A; Weiel, JE1
Biryahwaho, B; Dondero, T; Downing, R; Hu, DJ; Lal, R; Mastro, T; Nkengasong, J; Pieniazek, D; Rayfield, M; Soriano, V; Tanuri, A; Wiktor, SZ1
Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kurowski, M; Notheis, G; Wintergerst, U1
Blanchard, SG; Furfine, ES; Ittoop, O; Jain, RG; Lenhard, JM; Orband-Miller, LA; Paulik, MA; Weiel, JE1
Bart, PA; Chapuis, AG; Chave, JP; Corpataux, JM; Graziosi, C; Halkic, N; Lazzarin, A; McDade, H; Meuwly, JY; Meylan, P; Munoz, M; Pantaleo, G; Perrin, L; Rizzardi, GP; Spreen, W; Tambussi, G; Yerly, S1
Duval, X; Farinotti, R; Lamotte, C; Le Moing, V; Leport, C; Longuet, C; Peytavin, G; Vildé, JL1
Korn, K; Moschik, B; Paatz, C; Schmidt, B; Uberla, K; Walter, H1
Conway, B; Shafran, SD1
Tavel, JA1
Brothers, CH; Feinberg, J; Fischl, M; Goodgame, JC; Hardy, WD; Jablonowski, H; Morrow, P; Nacci, P; Pedneault, L; Pottage, JC; Stein, A; Vafidis, I; Yeo, J1
Bart, PA; Chapuis, AG; Lazzarin, A; Pantaleo, G; Rizzardi, GP; Tambussi, G1
Gillotin, C; Lou, Y; Sadler, BM; Stein, DS2
Koch, CA; Wolkersdoerfer, G1
Aungst, BJ; Bulgarelli, JP; Nguyen, NH; Oates-Lenz, K1
Goa, KL; Noble, S1
Brophy, DF; Chittick, GE; Israel, DS; Kristoff, D; Lou, Y; Patron, R; Polk, RE; Sadler, BM; Stein, DS; Symonds, WT1
Acosta, E; Currier, JS; D'Aquila, RT; Eron, JJ; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, LM; Snyder, S; Sommadossi, JP; Tung, R1
Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ1
Brothers, C; Fetter, A; Millard, J; Pagano, G; Pedneault, L; Tymkewycz, P; Yeo, J1
Ishizawa, M; Komatsu, H1
Blom-Roosemalen, MC; Breimer, DD; de Boer, AG; Nabulsi, L; van der Sandt, IC; Voorwinden, HH; Vos, CM1
Garrett, L; Garris, C; Graham, N; Pedneault, L; Rogers, M; Scott, T1
Brouwer, KR; Huang, L; Polli, JW; Serabjit-Singh, C; Woolley, JL; Wring, SA1
Chittick, GE; Kerkering, TM; Lou, Y; Moore, KH; Polk, RE; Sadler, BM; Slain, D; Stein, DS; Studenberg, SD; Woolley, JL1
Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L1
Brothers, CH; Scott, TR; Stein, AJ1
Griswold, MP; Gunawan, S; Kahn, DG1
Levin, J2
Chang, HE1
Coppedge, B1
Baker, R; Bowers, M1
Grinberg, L1
Fakuda, D2
Bartnof, HS1
Gilden, D2
Highleyman, L3
Elwell, A1
Prescott, LM1
Gallant, JE1
James, JS1
Simmons, P1
Fornataro, K; Jefferys, R1
Arroyo, HT1
Bartnoff, H; Deeks, S; Follansbee, S1
Agosto, M1
Eron, JJ; Haubrich, R; Lang, W; Millard, J; Pagano, G; Pedneault, L; Snowden, W; Tisdale, M; Wolfram, J1
Iwamoto, A; Kotaki, H; Nakamura, T; Yamada, H1
Lloyd, PP; Lou, Y; Piliero, PJ; Preston, SL; Sadler, BM; Stein, DS1
Blanco, JL; Carné, X; Gatell, JM; López-Púa, Y; Mallolas, J; Sarasa-Nacenta, M1
Arrizabalaga, J; Clotet, B; Martínez-Picado, J; Ruiz, L1
Bartoli, A; Feroggio, M; Gianelli, L; Maserati, R; Montagna, M; Regazzi, MB; Villani, P1
Bakshi, S; Black, K; Kodoth, S; Pahwa, S; Scimeca, P1
Bourin, M; Dailly, E; Jolliet, P; Kergueris, MF; Thomas, L1
Antunes, F; Blake, D; Clumeck, N; Danner, SA; Haubrich, R; Millard, J; Mustafa, N; Myers, RE; Nacci, P; Schooley, RT; Sereni, D; Thompson, M; Tisdale, M; van Der Ende, ME1
Huff, B1
Carter, LH; Danger, DP; Furfine, ES; Hanlon, MH; Porter, DJ1
Bart, PA; Baumann, P; Eap, CB; Gallant, S; Golay, KP; Pantaleo, G; Rizzardi, PG1
Gantke, B; Kuschak, D; Mauss, S; Schmutz, G1
Mazzullo, JM; Piliero, PJ1
Burger, D; Fätkenheuer, G; Kamps, R; Römer, K; Salzberger, B1
D'Aquila, RT; Hanna, GJ; Zachary, KC1
Atzori, C; Cargnel, A; Fantoni, G; Valerio, A1
Eron, JJ; Gillotin, C; Haubrich, R; Lang, W; Lou, Y; Sadler, BM; Stein, DS1
Pereira, A; Taylor, S1
Gatell, JM1
Gatanaga, H; Gorelick, RJ; Kavlick, MF; Mardy, S; Mitsuya, H; Nagashima, K; Summers, MF; Suzuki, Y; Tang, C; Tsang, H; Yoshimura, K1
Clavel, F; Damond, F; Descamps, D; Duval, X; Lamotte, C; Leport, C; Peytavin, G; Race, E; Vilde, JL1
Kuschak, D; Mauss, S; Schmutz, G1
Sadler, BM; Stein, DS1
Cohen, DM; James, CW; Matalia, MD; McNelis, KC; Szabo, S1
Cohen, MS; Dunn, JA; Eron, JJ; Kenney, KB; Pereira, AS; Tidwell, RR1
Ait-Khaled, M; Brosgart, CL; Eron, JJ; Falloon, J; Feinberg, J; Flanigan, TP; Hammer, SM; Kraus, PW; Masur, H; Murphy, R; Thomas, DA; Torres, R1
Gao, W; Kishida, T; Okamoto, H; Shibata, N; Takada, K; Yoshikawa, Y1
Elston, R; Harris, W; Klein, A; Maguire, M; Manohitharajah, V; May, J; Parker, H; Randall, S; Shortino, D; Snowden, W; Tisdale, M; Xu, F; Yeo, J1
Sadler, BM; Sale, M; Stein, DS1
Solignac, M1
Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J1
Jaillon, P; Poirier, JM; Robidou, P2
Jain, RG; Lenhard, JM1
Corral, A; de Mendoza, C; Gallego, O; Soriano, V1
Beauchaine, J; Clotet, B; D'Aquila, RT; Frost, SD; Martinez-Picado, J; Petropoulos, CJ; Prado, JG; Ruiz, L; Wrin, T1
Bonaventure-Paci, S; Demarles, D; Fosse, S; Gillotin, C; Taburet, AM; Vincent, I1
Brill, M; Farthing, C; Graham, E; Khanlou, H1
Alexander, C; Harris, M; Montaner, JS; O'Shaughnessy, M1
Piliero, PJ1
Perrin, L1
Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K1
Brouwer, KR; Edwards, JE; McNamara, PJ1
Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ1
Elston, RC; Furfine, E; Griffin, P; Guinea, R; Hanlon, MH; Kleim, JP; Macmanus, S; Maguire, MF; Parkin, N; Petropoulos, C; Porter, DJ; Richards, N; Snowden, BW; Tisdale, M; Wolfram, J; Wrin, T1
Bihel, F; Bonnet, B; Chermann, JC; Courcambeck, J; De Michelis, C; Kraus, JL; Priem, G; Rocheblave, L1
Acosta, EP; Eron, JJ; Fiscus, SA; Gerber, JG; Gulick, RM; Murphy, RL; Pereira, AS; Smeaton, LM; Snyder, S; Tidwell, RR1
Freire, E; Ohtaka, H; Velázquez-Campoy, A; Xie, D1
Buchanan, TA; Dubé, MP; Edmondson-Melançon, H; Goodwin, D; Johnson, D; Martinez, C; Qian, D; Sattler, FR; Williams, V1
Bye, C; Falcoz, C; Fuder, H; Hardman, TC; Jenkins, JM; Kenney, KB; Prince, WT; Studenberg, S1
Gamarnik, A; Parkin, N; Resch, W; Swanstrom, R; Ziermann, R1
Gao, W; Kageyama, M; Kimura, K; Kishida, T; Shibata, N; Takada, K; Yoshikawa, Y1
Bagossi, P; Boross, P; Copeland, TD; Fehér, A; Harrison, RW; Louis, JM; Mahalingam, B; Torshin, IY; Tözsér, J; Weber, IT1
Bennett, KK; Hammer, SM; Labbé, L; Lu, JF; Mellors, J; Pfister, M; Rosenkranz, S; Sheiner, LB1
Chaudry, NI; Eron, JJ; Fiscus, SA; Kashuba, AD; Naderer, OJ; Pereira, AS; Wire, MB1
Bates, SM; Nakielny, RA; Page, KB; Talbot, MD1
Bacconier, J; Basso, S; Durand, A; Lacarelle, B; Poizot-Martin, I; Quinson, AM; Ravaux, I; Solas, C1
Aweeka, FT; Chi, J; Jayewardene, AL; Motoya, T; Stone, JA1
Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ1
Fusco, G; Liao, Q; Paulsen, D; Ross, L; Shaefer, M; St Clair, M1
Fenton, M; Hall, M; Tong, C1
Gaylord, G1
Garrett, M; Hee, B; Kerr, BM; Petersen, C; Tran, JQ1
Bidault, R; Bollens, D; Choudet, N; Demarles, D; Gillotin, C; Goujard, C; Meynard, JL; Rousseau, C; Taburet, AM; Vincent, I1
Ershov, FI; Kas'ianova, NV; Vasil'ev, AN1
Brosen, K; Justesen, US; Klitgaard, NA; Pedersen, C2
Ait Mohand, H; Bonmarchand, M; Bossi, P; Bricaire, F; Cacace, R; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Peytavin, G; Simon, A; Wirden, M1
Fukumoto, K; Fukushima, K; Gao, W; Inoue, Y; Kageyama, M; Nishimura, A; Shibata, N; Tadano, J; Takada, K; Yamasaki, D; Yoshikawa, Y1
Bowers, G; Cazali, N; Cresteil, T; Pons, G; Rey, E; Sonnier, M; Tréluyer, JM1
Hamm, G; Hube, B; Korting, HC; Krnjaic, N; Niewerth, M; Schaller, M1
Bogner, JR; Eberle, J; Goebel, FD; Troendle, U1
Aarnoutse, RE; Burger, DM; Droste, JA; Hekster, YA; Koopmans, PP1
Chappey, C; Parkin, NT; Petropoulos, CJ1
Zolopa, AR1
Ait-Khaled, M; Falloon, J; Griffin, P; Rakik, A; Richards, N; Stone, C; Thomas, D; Tisdale, M1
DiFrancesco, R; Frerichs, VA; Keil, K; Morse, G1
Gathe, JC; Griffith, S; Hernandez, JE; Lancaster, CT; Liao, Q; Nadler, JP; Pappa, KA; Pollard, RB; Richmond, GJ1
Korn, K; Moschik, G; Paatz, C; Schmidt, B; Schnell, T; Thein, C; Walter, H1
Brenner, B; Detorio, M; Diallo, K; Götte, M; Moisi, D; Oliveira, M; Wainberg, MA1
Bates, M; Hellmann, N; Huang, W; Petropoulos, C; Wrin, T1
Hruz, PW; Koster, JC; Nichols, CG; Qiu, H; Remedi, MS1
Bevans, P; Furfine, E; Kazmierski, WM; Spaltenstein, A; Yang, H1
Berenson, CS; Cloen, D; DiFrancesco, R; Giovanniello, AA; Hewitt, RG; Keil, K; Shelton, MJ1
Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R1
Elston, R; Paulsen, D; Ross, L; Snowden, W; Tisdale, M1
Cammalleri, C; Colby-Germinario, SP; Germinario, RJ; Wainberg, MA1
Bilcer, G; Boross, P; Devasamudram, T; Gaddis, L; Ghosh, AK; Harrison, RW; Kincaid, JF; Koh, Y; Maeda, K; Mitsuya, H; Nakata, H; Ogata, H; Tie, Y; Volarath, P; Wang, YF; Weber, IT1
Becker, S; Carlson, M; DeJesus, E; Delehanty, J; DeMasi, R; Haas, FF; Haubrich, R; Henry, D; Lalezari, JP; Northfelt, DW; Powderly, W; Richmond, G; Riddler, S; Salgo, M; Sista, PR; Thompson, M; Valentine, F; Wolfe, P; Wright, D1
Cane, PA; de Ruiter, A; Easterbrook, PJ; Fisher, M; Leen, C; Li, X; Murphy, M; Pillay, D; Sabin, CA; Vlahakis, E; Wilkins, E1
Ailhaud, G; Azoulay, S; Dani, C; Duval, D; Guedj, R; Vernochet, C1
Lam, E; Parkin, NT1
Carosi, G; Donati, E; Lo Caputo, S; Mazzotta, F; Moretti, F; Patroni, A; Quiros-Roldan, E; Scudeller, L; Torti, C; Vivarelli, A1
Bilello, JA; Drusano, GL; Piliero, PJ; Preston, SL; Stein, DS; Symonds, WT1
Auclair, M; Capeau, J; Caron, M; Kornprobst, M; Sterlingot, H1
Aquaro, S; Caliò, R; Di Santo, F; Francesconi, M; Guenci, T; Perno, CF1
Bassetti, D; Castagna, A; De Pascalis, CR; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Seminari, E1
Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J1
Berger, F; Jaeger, H; Kurowski, M; Mauss, S; Rockstroh, JK; Schmutz, G; Scholten, S; Wolf, E1
Joseph, AT; Khoo, SH1
Bulgheroni, E; Chou, TC; Citterio, P; Croce, F; Galli, M; Lo Cicero, M; Rusconi, S; Soster, F; Viganò, O1
Baker, CT; Furfine, ES; Hale, MR; Reynolds, DJ; Salisbury, JA; Searle, AD; Spaltenstein, A; Studenberg, SD; Todd, D; Tung, RD1
de Mendoza, C; González de Requena, D; González-Lahoz, J; Martin-Carbonero, L; Soriano, V; Valer, L1
Ballow, C; Hendrix, CW; Lou, Y; Piliero, PJ; Preston, SL; Stein, DS; Wire, MB1
Barrail, A; Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM; Vincent, I1
Chou, S; Marousek, GI; Murphy, MD1
Boeri, E; Castagna, A; Danise, A; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Seminari, E1
Baldini, F; Cauda, R; Cingolani, A; De Luca, A; Di Giambenedetto, S; Hoetelmans, RM1
Brun-Vezinet, F; Clavel, F; Collin, G; Costagliola, D; Dalban, C; Descamps, D; Girard, PM; Lastere, S1
DeGoey, DA; Randolph, JT1
Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kruse, G; Kurowski, M; Notheis, G; Stocker, H; Wintergerst, U1
Barnaby, RJ; Baughman, TM; Bertolotti, L; Humphreys, JE; Jordan, KH; Mote, AL; Polli, JW; Read, KD; Serabjit-Singh, CJ; Vitulli, G; Webster, LO1
Corbett, AH; Eron, JJ; Fiscus, SA; Kashuba, AD; Rezk, NL1
Boulmé, R; Clevenbergh, P; Dellamonica, P; Kirstetter, M1
Cattelan, AM; Clumeck, N; Katlama, C; Marquez, M; Pedro, Rde J; Pulido, F; Thomas, R; Tymkewycz, P; Zhu, C1
Honda, Y; Izawa, K; Katayama, S; Kishibata, N; Kojima, M; Suzuki, T1
Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M1
Angarano, G; Carosi, G; Lo Caputo, S; Mazzotta, F; Monno, L; Patroni, A; Quiros-Roldan, E; Saracino, A; Tinelli, C; Tirelli, V; Torti, C1
Chappuy, H; Dimet, J; Firtion, G; Fouché, M; Mandelbrot, L; Pons, G; Rey, E; Tréluyer, JM1
Arasteh, K; Eron, J; Livrozet, JM; Millard, J; Naderer, OJ; Teofilo, E; Trepo, C; Wire, MB; Wood, R; Yeo, J1
Brill, M; Campo, R; Chu, HM; Garg, V; Jayaweera, DT; Kolber, MA; Rodriguez, A; Tanner, T1
Buchanan, TA; Considine, RV; Deeg, MA; Degawa-Yamauchi, M; Dubé, MP; Edmondson-Melançon, H; Hernandez, J; Sattler, FR; Shankar, S; Young, EM1
Chêne, G; Clavel, F; Droz, C; Girard, PM; Le Tiec, C; Morand-Joubert, L; Raguin, G; Taburet, AM1
Bigelow, GE; Christopher, J; Fuchs, EJ; Hendrix, CW; Lou, Y; Martinez, E; Snidow, JW; Wakeford, J; Wire, MB1
de Béthune, MP; King, NM; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Wigerinck, P1
Blanche, S; Johnson, M; Lou, Y; Randall, S; Stein, DS1
Aldinger, T; Ayrton, A; Bentz, J; Ellens, H; Mittal, A; Polli, JW; Tran, TT1
Carter, HL; Danger, D; Furfine, ES; Hanlon, MH; Kaldor, IW; Miller, JF; Porter, DJ; Samano, VA; Shu, AY; Spaltenstein, A1
Klein, HH; Meier, M; Schütt, M; Zhou, J1
Chadwick, EG; Homans, JD; Kovacs, A; Lou, Y; Symonds, WT; Yogev, R1
Baker, KL; Ford, SL; Lou, Y; Stein, DS; Wire, MB1
Acosta, EP; Collier, AC; Downey, GF; Eshleman, SH; Kashuba, AD; Klingman, K; Mellors, JW; Scott, TR; Tierney, C; Vergis, EN1
Arvieux, C; Tribut, O1
Jenwitheesuk, E; Samudrala, R1
Boutton, CW; De Bondt, HL; De Jonge, MR1
Chen, YS; Hsu, MF; Tsai, JJ; Wang, JP1
Dekhtyar, T; Flentge, CA; Kempf, DJ; Klein, LL; Randolph, JT; Stoll, VS; Sun, M; Yeung, CM; Zhao, C1
Brown, AJ; Clotet, B; Frost, SD; Martinez-Picado, J; Parkin, NT; Petropoulos, CJ; Ruiz, L; Wrin, T1
Arnedo, M; Biglia, MA; Blanco, JL; García, F; Gatell, JM; Laguno, M; Larrousse, M; Leon, A; Lonca, M; Mallolas, J; Martínez, E; Milinkovic, A; Miró, JM; Pumarola, T1
Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K1
Castagna, A; Cusato, M; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Regazzi, M; Seminari, E; Villani, P1
Adams, E; Brizz, B; Difrancesco, R; Morse, GD; Para, MF; Reichman, RC; Rosenkranz, S; Segal, Y; Yarasheski, KE1
Chai, H; Chen, C; Li, M; Lin, PH; Lumsden, AB; Yan, S; Yang, H; Yao, Q1
Ayrton, A; Bentz, J; Ellens, H; Polli, JW; Tran, TT1
Hruz, PW; Yan, Q1
El-Shourbagy, TA; Fan, L; Kim, GE; Naxing Xu, R1
Allred, KF; Smart, EJ; Wilson, ME1
Elston, R; Kleinkauf, N; Schürmann, D; Suttorp, N; Wünsche, T; Xu, F1
Bhatti, L; Farthing, C; Khanlou, H1
Augustijns, P; Brouwers, J; Lammert, F; Tack, J1
Barrail, A; Furlan, V; Le Tiec, C; Paci-Bonaventure, S; Taburet, AM; Vincent, I1
Backman, JT; Granfors, MT; Kajosaari, LI; Laitila, J; Neuvonen, PJ; Wang, JS1
Shelton, MJ; Studenberg, S; Wire, MB1
Chang, CE; McCammon, JA; Shen, T; Tozzini, V; Trylska, J1
Baker, KL; Berrey, MM; Jones, LS; Lou, Y; Shelton, MJ; Thomas, GJ; Wire, MB1
Bagossi, P; Boross, P; Fehér, A; Kádas, J; Miklóssy, G; Oroszlan, S; Sperka, T; Tözsér, J; Weber, IT1
Bacheler, L; Corral, A; de Mendoza, C; Pattery, T; Soriano, V; Valer, L1
Borland, J; Ford, SL; Lou, Y; Min, SS; Shelton, MJ; Wire, MB; Xue, ZG; Yuen, G1
Huynh, P; Kohli-Pamnani, A; Lobo, F1
Bonora, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Gennari, W; Gerunda, GE; Guaraldi, G; Luzi, K; Masetti, M; Motta, A; Pecorari, M1
Li, WP; Schutt, M; Xiang, Z; Zhou, JQ1
Chang, MS; El-Shourbagy, TA; Kim, EJ1
Harrer, T; Horn, AH; Meiselbach, H; Sticht, H1
Furfine, E; Kazmierski, WM; Spaltenstein, A; Wright, LL1
de Hoon, J; Van Wijngaerden, E; Verbesselt, R1
Balfour, HH; Brundage, RC; Vezina, HE; Weller, DR1
Lancaster, CT; Lou, Y; Luber, AD; Pappa, KA; Ruane, PJ; Shelton, MJ; Wire, MB1
Doron-Faigenboim, A; Pupko, T1
Brenner, BG; Moisi, D; Ntemgwa, M; Oliveira, M; Wainberg, MA1
Acharya, P; Ayrton, A; Bentz, J; Ellens, H; Polli, JW; Tran, TT1
Chêne, G; Clavel, F; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM1
Augustijns, P; Brouwers, J; Tack, J2
Choi, SO; Kashuba, AD; Rezk, NL1
Chang, CE; Chen, W; Gilson, MK1
Adams, E; Bilic, S; DiFrancesco, R; Forrest, A; Morse, GD; Okusanya, O; Para, MF; Reichman, RC; Rosenkranz, S; Yarasheski, KE1
Hou, T; Yu, R1
Berthé, H; de Truchis, P; Delaugerre, C; Galperine, T; Long, K; Mathez, D; Peytavin, G1
Ballow, CH; Borland, J; Lewis, EW; Lin, J; Lou, Y; Shelton, MJ; Wire, MB; Yuen, G1
Banik, N; Breske, A; Kruse, G; Kurowski, M; Mazur, D; Richter, H; Stocker, H; Walli, RK1
Crane, HM; Harrington, RD; Kestenbaum, B; Kitahata, MM1
Bastiani, E; Benedetti, F; Berti, F; Campaner, P; Donadel, E; Montagna, M; Regazzi, M; Rinaldi, S; Savoini, A; Venturini, R1
Castagna, A; De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Gianotti, N; Lazzarin, A; Schira, G; Seminari, E; Soldarini, A; Uberti-Foppa, C1
De Bona, A; Dorigatti, F; Galli, L; Gentilini, G; Seminari, E; Soldarini, A; Spagnuolo, V; Uberti-Foppa, C1
Adams, E; Hoogmartens, J; Van Schepdael, A; Yekkala, R1
Asmuth, DM; Kung, HJ; Libertini, SJ; Mudryj, M; Rodriguez, V; Tepper, CG1
Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C1
Acharya, P; Ayrton, A; Bentz, J; Ellens, H; O'Connor, MP; Polli, JW1
Deray, G; Izzedine, H; Janus, N; Karie, S; Launay-Vacher, V; Laville, I1
Bui, T; Ho, RJ; Hsiao, P; Unadkat, JD1
Aweeka, F; Grunfeld, C; Lee, GA; Lo, JC; Mulligan, K; Rao, M; Schambelan, M; Schwarz, JM1
de Béthune, MP; De Meyer, S; Picchio, G1
Bruzzone, B; Cenderello, G; Dentone, C; Di Biagio, A; Ferrea, G; Icardi, G; Mularoni, A; Rosso, R; Viscoli, C1
Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F1
Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M1
Barrail-Tran, A; Chêne, G; Clavel, F; Dam, E; Girard, PM; Le Tiec, C; Morand-Joubert, L; Poizat, G; Raguin, G; Taburet, AM1
Diaz, RS; Ferreira, PA; Tenore, S1
Delgado, O; Murillas, J; Riera, M; Ventayol, P1
Ali, A; Altman, MD; Anjum, SG; Cao, H; Chellappan, S; Fernandes, MX; Gilson, MK; Kairys, V; Nalam, MN; Rana, TM; Reddy, GS; Schiffer, CA; Tidor, B1
Bigelow, GE; Cao, YJ; Causon, RC; Fuchs, EJ; Hendrix, CW; Lancaster, CT; Lou, Y; Martinez, E; McCabe, S; Radebaugh, C; Smith, PF; Wire, MB1
Feicke, A; Oertle, D; Rentsch, KM; Strebel, RT1
Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T1
Ghosh, AK; Kovalevsky, AY; Weber, IT1
Louis, JM; Sayer, JM1
Boesmans, D; Di Fazio, V; Elens, L; Haufroid, V; Vanbinst, R; Veriter, S; Wallemacq, P1
Allison, TJ; Coburn, CA; Dandache, S; Holloway, MK; Oliveira, M; Panchal, C; Stranix, BR; Vacca, JP; Wainberg, MA; Wu, JJ1
Aoki, M; Aoki-Ogata, H; Koh, Y; Maeda, K; Mitsuya, H; Miyakawa, T; Venzon, DJ; Yoshimura, K1
Hidalgo Tenorio, C; Pasquau Liaño, J1
Anderson, PL; Clay, PG; Glaros, AG; McRae, M1
Dyachenko, A; Grunfeld, C; Kim, S; Lee, GA; Mulligan, K; Patzek, S; Schambelan, M; Schwarz, JM; Wen, M1
Bihani, SC; Das, A; Ferrer, JL; Hosur, MV; Prashar, V1
Chen, J; Chen, L; Gurley, E; Hylemon, PB; Pandak, WM; Sanyal, AJ; Studer, E; Sun, L; Wang, G; Wang, JY; Wang, X; Wu, X; Zha, W; Zhang, L; Zhou, H1
Andrews, M; Condoluci, DV; Luber, AD; Olson, K; Pakes, GE; Pappa, KA; Peloquin, CA; Slowinski, PD1
Braga-Silva, LA; Mogami, SS; Santos, AL; Silva-Neto, ID; Valle, RS1
Dirauf, P; Meiselbach, H; Sticht, H1
Ciurlionis, R; Degoey, DA; Kempf, DJ; Klein, LL; Marsh, K; Randolph, JT; Spear, B; Waring, JF1
Annaert, P; Augustijns, P; Camus, S; Ye, ZW1
Alam, S; Dinello, D; Israr, M; Kishel, JJ; Meyers, C; Mitchell, D1
Blanco, J; Bofill, M; Cabrera, C; Clotet, B; Cunyat, F; Marfil, S; Puig, T; Ruiz, L1
Annaert, P; Augustijns, P; Brouwers, J; Mols, R1
Boccara, F; Costagliola, D; Cotte, L; Gilquin, J; Lang, S; Mary-Krause, M; Partisani, M; Simon, A1
Harrison, RW; Kovalevsky, AY; Shen, CH; Wang, YF; Weber, IT1
Baki, L; Baumgarten, CM; Deng, W; Yin, J; Zhou, H1
Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP1
Agniswamy, J; Amano, M; Aoki, M; Baldridge, A; Ghosh, AK; Miguel, SG; Mitsuya, H; Rao, KV; Wang, YF; Weber, IT; Xu, CX1
Adnot, S; Amsellem, V; Brégeon, J; Dubois-Randé, JL; Gary-Bobo, G; Houssaini, A; Marcos, E; Pacaud, P; Perrin, A; Rideau, D; Savale, L; Sitbon, O1
Browning, MR; Drexler, DM; Morgan, DG; Olah, TV1
de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C1
Amano, M; Aoki, M; Chapsal, B; Das, D; Ghosh, AK; Ide, K; Koh, Y; Leschenko, S; Mitsuya, H; Yedidi, RS1
Hoffmann, HH; Kunz, A; Palese, P; Shaw, ML; Simon, VA1
Nsanzabana, C; Rosenthal, PJ1
Cieplak, P; Deng, NJ; Lai, L; Zhang, P1
Dunn, BM; Goldfarb, NE; Gustchina, A; Li, M; Matúz, K; Namwong, S; Tözsér, J; Wlodawer, A1
Abraham, F; Acharya, P; Agnani, D; Bentz, J; Ellens, H; Martinez, E; Tobin, F; Tran, TT1
Borkowsky, W; DiMeglio, LA; Geffner, ME; Hazra, R; Jacobson, DL; Miller, TL; Patel, K; Silio, M; Van Dyke, RB; Worrell, C1
Appel, DI; Markowitz, JS; Peloquin, CA; Peterson, YK; Rhoades, JA; Zhu, HJ1
Boross, PI; Chiu, TY; Ghosh, AK; Harrison, RW; Louis, JM; Tie, Y; Tozser, J; Wang, YF; Weber, IT1
Best, BM; Capparelli, E; Clifford, DB; Collier, AC; Croteau, D; Ellis, RJ; Gelman, BB; Grant, I; Letendre, S; Marra, CM; McArthur, J; McCutchan, JA; Morgello, S; Rossi, SS; Simpson, DM; Way, L1
Hu, Y; Huang, N; Li, S; Xing, W; Yan, J; Yang, LM; Zheng, YT1
Abecasis, AB; Arts, EJ; Camacho, RJ; Diaz, RS; Herchenröder, O; Lalonde, MS; Ratcliff, A; Santos, AF; Soares, MA; Tebit, DM1
Kar, P; Knecht, V1
Aalinkeel, R; Law, WC; Mahajan, SD; Nair, BB; Prasad, PN; Reynolds, J; Roy, I; Schwartz, SA; Yong, KT1
Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Gargiulo, M; Lucariello, A; Manente, L; Parrella, G; Parrella, R; Perna, A; Viglietti, R1
Furukawa, A; Katahira, M; Matsunaga, S; Morishita, R; Ode, H; Ryo, A; Sakuma, R; Sato, H; Sawasaki, T; Sugiura, W; Takaori-Kondo, A; Yamamoto, N1
Furukawa, A; Ikegami, T; Katahira, M; Kobayashi, N; Kodaki, T; Matsunaga, S; Morishita, R; Nagata, T; Okamura, H; Ryo, A; Takaori-Kondo, A1
Baldi, A; Chirianni, A; De Luca, A; Esposito, V; Galati, R; Manente, L; Montesarchio, V; Pagliano, P; Parrella, G; Parrella, R; Spugnini, EP; Verdina, A; Viglietti, R1
Liu, L; Unadkat, JD1
Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN1
Bandaranayake, RM; King, NM; Mittal, S; Nalam, MN; Nalivaika, EA; Prabu-Jeyabalan, M; Schiffer, CA; Yilmaz, NK1
Amano, M; Aoki, M; Campbell, JR; Das, D; Ghosh, AK; Mitsuya, H; Rao, KV; Salcedo-Gómez, PM; Tojo, Y; Xu, CX1
Ai, N; Helsley, RN; Park, SH; Sui, Y; Welsh, WJ; Zhou, C1
Agniswamy, J; Ghosh, AK; Louis, JM; Rao, KV; Sayer, JM; Shen, CH; Wang, YF; Weber, IT; Xu, CX1
Commenges, D; Drylewicz, J; Guedj, J; Prague, M; Thiébaut, R1
Blakeley, MP; Ghosh, AK; Keen, DA; Kovalevsky, AY; Langan, P; Mustyakimov, M; Waltman, MJ; Weber, IT1
Bridges, AS; Dufek, MB; Thakker, DR1
Leonis, G; Papadopoulos, MG; Steinbrecher, T1
Bow, DA; Chiou, WJ; de Morais, SM; Kikuchi, R; Li, X; Voorman, RL1
Ahmed, Z; Bentz, J; Ellens, H; Hidalgo, IJ; Li, J; Li, L; Lumen, AA; Meng, Z; Owen, A1
Borland, J; Chen, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T1
Haugaard, SB1
Barbour, AM; Gibiansky, L; Wire, MB1
Chen, J; Liang, Z; Wang, W; Yi, C; Zhang, Q; Zhang, S1
Branquinha, MH; D Avila-Levy, CM; Menna-Barreto, RF; Sangenito, LS; Santos, AL1
Amano, M; Das, D; Ghosh, AK; Mitsuya, H; Nyalapatla, PR; Parham, GL; Salcedo-Gómez, PM; Tojo, Y1
Shao, Q; Shi, J; Wang, J; Yu, Y; Zhu, W1
Duan, R; Lazim, R; Zhang, D1
Aweeka, F; Collier, AC; Dumond, JB; Kashuba, AD; Mollan, K; Rigdon, J; Tierney, C1
Raines, RT; Windsor, IW1
Chen, J; Wang, X; Zhang, JZ; Zhang, Q; Zhu, T1
Acharjee, S; Asahchop, EL; Baker, GB; Power, C; Vivithanaporn, P1
Ganapathi, U; Gunaseelan, S; Myers, DR; Nelson, AG; Palombo, MS; Samizadeh, M; Singh, Y; Sinko, PJ; Szekely, Z; Zhang, X1
Alibés, A; Gil, V; Guallar, V; Hosseini, A; Noguera-Julian, M; Orozco, M; Paredes, R; Soliva, R1
Amano, M; Bulut, H; Das, D; Delino, NS; Ghosh, AK; Mitsuya, H; Salcedo-Gómez, PM; Sheri, VR; Yedidi, RS; Zhao, R1
Bentz, J; Ellens, H; Meng, Z1
Bao, J; Chen, J; Huang, G; Jiang, W; Li, C; Li, T; Li, X; Qi, P; Shi, W; Wang, H; Wang, Y1
Alteri, C; Aquaro, S; Borrajo, A; Bruno, R; Modesti, A; Perno, CF; Pollicita, M; Ranazzi, A; Svicher, V1
Camproux, AC; Cano Contreras, ME; Descamps, D; Flatters, D; Regad, L; Triki, D; Visseaux, B1
Chen, J; Peng, C; Wang, J; Zhu, W1
Augustijns, P; Braeckmans, M; Brouwers, J; Masuy, I; Servais, C; Tack, J1
Alviano, DS; Gonçalves, DS; Granato, MQ; Kneipp, LF; Pessolani, MCV; Rosa, TLSA; Santos, ALS; Seabra, SH; Sousa, IS1
Wang, RG; Zhang, HX; Zheng, QC1
Deeks, HM; Glowacki, DR; Hare, SR; Mulholland, AJ; O'Connor, MB; Walters, RK1
Behera, S; Das, P; Ghosh, P; Kumari, B; Mandal, A; Mazire, PH; Purkait, B; Roy, A1
Liu, WT; Sun, HB; Wang, W; Wu, SL; Yu, YX; Zhang, LL1

Reviews

27 review(s) available for carbamates and amprenavir

ArticleYear
In vitro selection and characterization of VX-478 resistant HIV-1 variants.
    Advances in experimental medicine and biology, 1998, Volume: 436

    Topics: Carbamates; Drug Resistance; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Protein Conformation; Sulfonamides

1998
Amprenavir.
    Drugs, 1998, Volume: 55, Issue:6

    Topics: Animals; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Rats; RNA, Viral; Sulfonamides

1998
Resistance to human immunodeficiency virus type 1 protease inhibitors.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:11

    Topics: Carbamates; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Nelfinavir; Pyridines; Pyrones; Ritonavir; Saquinavir; Structure-Activity Relationship; Sulfonamides

1998
Clinical update: new drugs for HIV/AIDS.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 1999, Volume: 8, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chemistry, Pharmaceutical; Cyclopropanes; Dideoxynucleosides; Drug Approval; Furans; HIV Protease Inhibitors; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

1999
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine

1999
Coming therapies: amprenavir.
    International journal of clinical practice. Supplement, 1999, Volume: 103

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides

1999
HIV protease as a target for retrovirus vector-mediated gene therapy.
    Biochimica et biophysica acta, 2000, Mar-07, Volume: 1477, Issue:1-2

    Topics: Amino Acid Sequence; Carbamates; Furans; Genetic Therapy; Genetic Vectors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lentivirus; Models, Molecular; Molecular Structure; Nelfinavir; Retroviridae; Ritonavir; Saquinavir; Sulfonamides; Transfection

2000
Targeting the HIV-protease in AIDS therapy: a current clinical perspective.
    Biochimica et biophysica acta, 2000, Mar-07, Volume: 1477, Issue:1-2

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Binding Sites; Carbamates; Clinical Trials as Topic; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Ritonavir; Saquinavir; Sulfonamides

2000
Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
    Clinical therapeutics, 2000, Volume: 22, Issue:5

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Furans; HIV Protease Inhibitors; Humans; Sulfonamides

2000
Ongoing trials in HIV protease inhibitors.
    Expert opinion on investigational drugs, 2000, Volume: 9, Issue:4

    Topics: Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; United States; United States Food and Drug Administration

2000
Amprenavir: a review of its clinical potential in patients with HIV infection.
    Drugs, 2000, Volume: 60, Issue:6

    Topics: Animals; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Molecular Structure; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome

2000
[Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 117, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mixed Function Oxygenases; Sulfonamides

2001
[Resistance to protease inhibitors].
    Enfermedades infecciosas y microbiologia clinica, 2001, Volume: 19, Issue:Monografic

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Mutation; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2001
Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.
    AIDS patient care and STDs, 2001, Volume: 15, Issue:7

    Topics: Adult; Carbamates; Diagnosis, Differential; Factor VIII; Furans; Hemophilia A; HIV Infections; HIV Protease Inhibitors; Humans; Intracranial Hemorrhages; Male; Sulfonamides; Tomography, X-Ray Computed

2001
Penetration of HIV-1 protease inhibitors into CSF and semen.
    HIV medicine, 2000, Volume: 1 Suppl 2

    Topics: Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Ritonavir; Saquinavir; Semen; Sulfonamides; Viral Load

2000
From amprenavir to GW433908.
    Journal of HIV therapy, 2001, Volume: 6, Issue:4

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Furans; HIV Infections; Humans; Organophosphates; Prodrugs; Sulfonamides

2001
Clinical pharmacology and pharmacokinetics of amprenavir.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:1

    Topics: Carbamates; Drug Interactions; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Tissue Distribution

2002
[A novel anti-HIV agent--agenerase].
    Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 2002, Volume: 47, Issue:8

    Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Sulfonamides

2002
Practical applications of viral fitness in clinical practice.
    Current opinion in infectious diseases, 2003, Volume: 16, Issue:1

    Topics: Carbamates; Drug Resistance, Viral; Furans; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Biological; Mutation; Sulfonamides; Viral Load; Virus Replication

2003
Differentiation of genotypic resistance profiles for amprenavir and lopinavir, a valuable aid for choice of therapy in protease inhibitor-experienced HIV-1-infected subjects.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:3

    Topics: Carbamates; Drug Resistance, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides

2003
Peptidomimetic inhibitors of HIV protease.
    Current topics in medicinal chemistry, 2004, Volume: 4, Issue:10

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane

2004
Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Drugs, 2005, Volume: 65, Issue:5

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphates; Ritonavir; Sulfonamides

2005
Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.
    Clinical pharmacokinetics, 2006, Volume: 45, Issue:2

    Topics: Adult; Carbamates; Drug Interactions; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Absorption; Organophosphates; Prodrugs; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution

2006
Quality control of protease inhibitors.
    Journal of pharmaceutical sciences, 2008, Volume: 97, Issue:6

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Chromatography, Liquid; Darunavir; Drug Contamination; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Organophosphates; Pyridines; Pyrimidinones; Pyrones; Quality Control; Ritonavir; Saquinavir; Sulfonamides

2008
Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
    AIDS (London, England), 2008, Jan-02, Volume: 22, Issue:1

    Topics: Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Treatment Outcome

2008
[Chemical characteristics, mechanism of action and antiviral activity of darunavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26 Suppl 10

    Topics: Administration, Oral; Carbamates; Clinical Trials as Topic; Cytochrome P-450 CYP3A; Darunavir; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Molecular Structure; Ritonavir; Sulfonamides

2008
Alteration in pancreatic islet function in human immunodeficiency virus.
    Endocrinology and metabolism clinics of North America, 2014, Volume: 43, Issue:3

    Topics: Carbamates; Furans; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Nelfinavir; Ritonavir; Sulfonamides

2014

Trials

88 trial(s) available for carbamates and amprenavir

ArticleYear
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.
    Antiviral research, 1996, Volume: 29, Issue:1

    Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Pyridines; Quinolines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine

1996
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
    The Journal of infectious diseases, 1999, Volume: 179, Issue:4

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Sulfonamides; Zidovudine

1999
Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.
    Antimicrobial agents and chemotherapy, 1999, Volume: 43, Issue:7

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Sulfonamides

1999
Sampling lymphoid tissue cells by ultrasound-guided fine needle aspiration of lymph nodes in HIV-infected patients. Swiss HIV Cohort Study.
    AIDS (London, England), 1999, Aug-20, Volume: 13, Issue:12

    Topics: Anti-HIV Agents; Biopsy, Needle; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Drug Therapy, Combination; Flow Cytometry; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Longitudinal Studies; Lymph Nodes; Lymphocyte Activation; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Ultrasonography

1999
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
    AIDS (London, England), 1999, Dec-03, Volume: 13, Issue:17

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; RNA, Viral; Safety; Sulfonamides; Time Factors; Viremia; Zidovudine

1999
Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.
    Pharmacotherapy, 1999, Volume: 19, Issue:12

    Topics: Adult; Antifungal Agents; Breath Tests; Carbamates; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Erythromycin; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Mixed Function Oxygenases; Sulfonamides; Time Factors

1999
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2000, Volume: 30, Issue:2

    Topics: Adult; Alkynes; Antiviral Agents; Area Under Curve; Base Sequence; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Oxazines; Phenotype; Pilot Projects; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2000
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:4

    Topics: Adult; Area Under Curve; Carbamates; Female; Furans; HIV Protease Inhibitors; HIV-1; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Protein Binding; Sulfonamides

2000
Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Area Under Curve; Biotransformation; Breath Tests; Carbamates; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Erythromycin; Furans; Half-Life; Humans; Liver Function Tests; Male; Mixed Function Oxygenases; Sulfonamides

2000
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
    The Journal of infectious diseases, 2000, Volume: 181, Issue:5

    Topics: Adult; Carbamates; Double-Blind Method; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; RNA, Viral; Semen; Sulfonamides; Virus Shedding; Zidovudine

2000
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    The Journal of infectious diseases, 2000, Volume: 182, Issue:3

    Topics: Carbamates; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Phenotype; Protein Binding; Ritonavir; Saquinavir; Sulfonamides

2000
Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
    AIDS (London, England), 2000, Sep-08, Volume: 14, Issue:13

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; CD4-CD8 Ratio; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lymph Nodes; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Viral Load

2000
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Antiviral therapy, 2000, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Zidovudine

2000
Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    AIDS (London, England), 2000, Oct-20, Volume: 14, Issue:15

    Topics: Adult; Anti-HIV Agents; Antigens, Fungal; Antigens, Viral; Antiretroviral Therapy, Highly Active; Candida albicans; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Cytomegalovirus; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Simplexvirus; Sulfonamides; T-Lymphocyte Subsets

2000
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Dideoxynucleosides; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; RNA, Viral; Sulfonamides

2001
Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:2

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Biotransformation; Breath Tests; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; Drug Interactions; Erythromycin; Furans; Humans; Male; Middle Aged; Mixed Function Oxygenases; Rifabutin; Rifampin; Sulfonamides

2001
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
    The Journal of infectious diseases, 2001, Mar-01, Volume: 183, Issue:5

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Male; Nevirapine; Odds Ratio; Prospective Studies; RNA, Viral; Safety; Stavudine; Sulfonamides; Time Factors; Treatment Outcome; Viral Load

2001
In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:3

    Topics: Adolescent; Adult; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; HIV Protease Inhibitors; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Orosomucoid; Sulfonamides

2001
Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection.
    Clinical therapeutics, 2000, Volume: 22, Issue:12

    Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Digestive System; Drug Therapy, Combination; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Paresthesia; Sulfonamides

2000
Safety profile and tolerability of amprenavir in patients enrolled in an early access program.
    Clinical therapeutics, 2001, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Sulfonamides

2001
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
    Journal of clinical pharmacology, 2001, Volume: 41, Issue:4

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Black People; Breath Tests; Carbamates; Carbon Radioisotopes; Follow-Up Studies; Furans; Half-Life; HIV Seronegativity; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sulfonamides; White People

2001
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2001, Apr-01, Volume: 26, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine

2001
Protease inhibitor trial started.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Carbamates; Furans; HIV Protease Inhibitors; Humans; Indinavir; Reverse Transcriptase Inhibitors; Sulfonamides

1998
Preliminary data on 141W94 reported.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine

1998
Phase III results presented on amprenavir triple combination.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:12

    Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine

1998
A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.
    Journal of acquired immune deficiency syndromes (1999), 2001, Apr-15, Volume: 26, Issue:5

    Topics: Adult; Aged; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Treatment Outcome

2001
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.
    AIDS (London, England), 2001, May-25, Volume: 15, Issue:8

    Topics: Administration, Oral; Adult; Body Mass Index; Carbamates; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exanthema; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Nausea; Ritonavir; Statistics, Nonparametric; Sulfonamides

2001
A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Antiviral therapy, 2001, Volume: 6, Issue:2

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Maximum Tolerated Dose; Phenotype; Sulfonamides; Time Factors; Treatment Outcome

2001
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:12

    Topics: Adult; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Indinavir; Male; Mixed Function Oxygenases; Nelfinavir; Orosomucoid; Saquinavir; Sulfonamides

2001
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    AIDS (London, England), 2002, 02-15, Volume: 16, Issue:3

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Phenotype; Retrospective Studies; RNA, Viral; Safety; Sulfonamides; Treatment Failure

2002
Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleos
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:3

    Topics: Carbamates; Cloning, Molecular; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genotype; HIV Core Protein p24; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sulfonamides

2002
Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:3

    Topics: Adolescent; Adult; Algorithms; Anti-HIV Agents; Carbamates; Computer Simulation; Drug Interactions; Female; Furans; Humans; Male; Middle Aged; Models, Biological; Monte Carlo Method; Reproducibility of Results; Ritonavir; Sulfonamides

2002
Single-dose pharmacokinetics of amprenavir coadministered with grapefruit juice.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:5

    Topics: Administration, Oral; Adult; Beverages; Carbamates; Citrus; Cross-Over Studies; Female; Food-Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Male; Sulfonamides

2002
Therapeutic vaccination in primary HIV infection, the Quest trial.
    Vaccine, 2002, May-06, Volume: 20, Issue:15

    Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine

2002
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    JAMA, 2002, Jul-10, Volume: 288, Issue:2

    Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load

2002
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
    The Journal of infectious diseases, 2002, Jul-15, Volume: 186, Issue:2

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral; Semen; Statistics, Nonparametric; Sulfonamides; Zidovudine

2002
Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers.
    Journal of clinical pharmacology, 2002, Volume: 42, Issue:8

    Topics: Adolescent; Adult; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Furans; Health; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Sulfonamides; Suspensions; Tablets

2002
Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.
    Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:2

    Topics: Adult; Biological Availability; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Mixed Function Oxygenases; Nelfinavir; Saquinavir; Sulfonamides

2002
Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
    Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:6

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; Delavirdine; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Longitudinal Studies; Male; Middle Aged; Reference Values; Sulfonamides

2002
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:1

    Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Ritonavir; Sulfonamides

2003
Pharmacokinetic interaction between amprenavir and delavirdine after multiple-dose administration in healthy volunteers.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Delavirdine; Drug Interactions; Furans; Humans; Male; Prospective Studies; Sulfonamides

2003
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:2

    Topics: Adult; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Predictive Value of Tests; Ritonavir; Sulfonamides; Viral Load

2003
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
    European journal of medical research, 2003, Feb-21, Volume: 8, Issue:2

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Viremia

2003
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Antiviral therapy, 2003, Volume: 8, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Salvage Therapy; Sulfonamides

2003
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
    BMC infectious diseases, 2003, Jun-10, Volume: 3

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV-1; Humans; Male; Ritonavir; RNA, Viral; Sulfonamides; Viral Load

2003
Effects of didanosine formulations on the pharmacokinetics of amprenavir.
    Pharmacotherapy, 2003, Volume: 23, Issue:7

    Topics: Administration, Oral; Adult; Anti-HIV Agents; Area Under Curve; Capsules; Carbamates; Cross-Over Studies; Didanosine; Drug Interactions; Drug Therapy, Combination; Female; Furans; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Sulfonamides; Tablets, Enteric-Coated; Time Factors

2003
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Antiviral therapy, 2003, Volume: 8, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Enfuvirtide; Female; Furans; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Peptide Fragments; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load

2003
HIV susceptibility to amprenavir: phenotype-based versus rules-based interpretations.
    The Journal of antimicrobial chemotherapy, 2003, Volume: 52, Issue:5

    Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Phenotype; Prospective Studies; Sulfonamides; Treatment Outcome

2003
In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:11

    Topics: Adult; Anti-HIV Agents; Antiviral Agents; Carbamates; Cell Line; Cells, Cultured; Drug Combinations; Female; Furans; HIV Antigens; Humans; Male; Middle Aged; Models, Biological; Protein Binding; Ritonavir; Sulfonamides; T-Lymphocytes; Tetrazolium Salts; Thiazoles; Time Factors

2003
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides

2004
A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir.
    HIV medicine, 2004, Volume: 5, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Lopinavir; Prospective Studies; Pyrimidinones; Ritonavir; Sulfonamides

2004
Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
    AIDS patient care and STDs, 2004, Volume: 18, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mutation; Patient Selection; Phenotype; Predictive Value of Tests; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load

2004
Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.
    AIDS (London, England), 2004, Apr-09, Volume: 18, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cholesterol; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Furans; Humans; Linear Models; Male; Middle Aged; Organophosphates; Oxazines; Prodrugs; Ritonavir; Sulfonamides; Triglycerides

2004
Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Clinical pharmacology and therapeutics, 2004, Volume: 75, Issue:4

    Topics: Administration, Oral; Adult; Antiretroviral Therapy, Highly Active; Biological Availability; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Middle Aged; Probability; Pyrimidinones; Risk Assessment; Ritonavir; Salvage Therapy; Severity of Illness Index; Single-Blind Method; Statistics, Nonparametric; Sulfonamides; Survival Rate; Treatment Outcome; Viral Load

2004
Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
    Journal of acquired immune deficiency syndromes (1999), 2004, Apr-01, Volume: 35, Issue:4

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pilot Projects; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides

2004
Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir.
    Antiviral therapy, 2004, Volume: 9, Issue:2

    Topics: Adult; Amino Acid Motifs; Amino Acid Sequence; Carbamates; Female; Furans; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Load

2004
Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:1

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Delavirdine; Dose-Response Relationship, Drug; Drug Combinations; Furans; Humans; Male; Prospective Studies; Spectrophotometry, Ultraviolet; Sulfonamides

2004
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.
    Journal of acquired immune deficiency syndromes (1999), 2004, Aug-01, Volume: 36, Issue:4

    Topics: Adult; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Viral Load

2004
Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients.
    HIV medicine, 2004, Volume: 5, Issue:4

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease; HIV-1; Humans; Logistic Models; Male; Mutation; Prospective Studies; Salvage Therapy; Sulfonamides; Viral Load

2004
A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults.
    HIV medicine, 2004, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Female; Furans; Genes, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Sulfonamides

2004
A 42-week open-label study to assess the pharmacokinetics, antiretroviral activity, and safety of amprenavir or amprenavir plus ritonavir in combination with abacavir and lamivudine for treatment of HIV-infected patients.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Aug-15, Volume: 39, Issue:4

    Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Ritonavir; Sulfonamides

2004
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
    Cardiovascular toxicology, 2004, Volume: 4, Issue:2

    Topics: Adult; Biomarkers; Blood Glucose; Carbamates; Drug Therapy, Combination; Female; Fibrinolysis; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Inflammation; Insulin Resistance; Male; Plasminogen Activator Inhibitor 1; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Sulfonamides; Tissue Plasminogen Activator

2004
Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Antiviral therapy, 2004, Volume: 9, Issue:4

    Topics: Adult; Aged; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load

2004
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
    Pharmacotherapy, 2004, Volume: 24, Issue:9

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Male; Methadone; Opioid-Related Disorders; Reaction Time; Stereoisomerism; Sulfonamides

2004
Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children.
    Journal of clinical pharmacology, 2004, Volume: 44, Issue:11

    Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Inhibitory Concentration 50; Male; Sulfonamides

2004
Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:1

    Topics: Area Under Curve; Carbamates; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome

2005
Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:1

    Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Combinations; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Magnesium Hydroxide; Organophosphates; Ranitidine; Sulfonamides

2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
    AIDS (London, England), 2005, Jan-28, Volume: 19, Issue:2

    Topics: Adult; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides; Treatment Outcome

2005
Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individuals.
    Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:8

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

2005
Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4

    Topics: Adult; Area Under Curve; Carbamates; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides

2006
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Prodrugs; Ritonavir; Sulfonamides

2007
Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results.
    AIDS (London, England), 2007, Jan-11, Volume: 21, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides

2007
Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state.
    Pharmaceutical research, 2007, Volume: 24, Issue:10

    Topics: Administration, Oral; Adult; Carbamates; Cross-Over Studies; Duodenum; Fasting; Feasibility Studies; Female; Food-Drug Interactions; Furans; Gastric Juice; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Secretions; Male; Organophosphates; Postprandial Period; Solubility; Sulfonamides; Tablets

2007
Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Organophosphates; Ritonavir; Sulfonamides; Treatment Outcome

2007
Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
    AIDS (London, England), 2007, Jun-19, Volume: 21, Issue:10

    Topics: Adenine; Anti-Retroviral Agents; Area Under Curve; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Organophosphates; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir

2007
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
    Antiviral therapy, 2007, Volume: 12, Issue:6

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides

2007
Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
    AIDS (London, England), 2007, Oct-18, Volume: 21, Issue:16

    Topics: Adult; Aged; Blood Glucose; Carbamates; Double-Blind Method; Energy Metabolism; Furans; Glucose Clamp Technique; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Resistance; Lactic Acid; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Sulfonamides

2007
Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5

    Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Phenotype; Prognosis; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load

2008
Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil.
    Journal of acquired immune deficiency syndromes (1999), 2008, Apr-01, Volume: 47, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Prospective Studies; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Outcome

2008
Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
    Pharmacotherapy, 2008, Volume: 28, Issue:7

    Topics: Adult; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Interactions; Female; Furans; Humans; Male; Methadone; Narcotics; Organophosphates; Prodrugs; Ritonavir; Stereoisomerism; Sulfonamides

2008
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
    Pharmacotherapy, 2009, Volume: 29, Issue:8

    Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Prodrugs; Pyridines; Ritonavir; Sulfonamides

2009
The acute effects of HIV protease inhibitors on insulin suppression of glucose production in healthy HIV-negative men.
    Journal of acquired immune deficiency syndromes (1999), 2009, Oct-01, Volume: 52, Issue:2

    Topics: Carbamates; Furans; Glucose; HIV Protease Inhibitors; Human Experimentation; Humans; Indinavir; Insulin; Male; Placebos; Ritonavir; Sulfonamides

2009
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
    HIV medicine, 2010, Volume: 11, Issue:3

    Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; Cross-Over Studies; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Organophosphates; Organophosphonates; Prodrugs; Ritonavir; Sulfonamides; Tenofovir; Young Adult

2010
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Antiviral therapy, 2010, Volume: 15, Issue:8

    Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load

2010
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load

2012
Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjects.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Adult; Area Under Curve; Carbamates; Drug Administration Schedule; Drug Interactions; Female; Furans; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; HIV Integrase; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Organophosphates; Oxazines; Piperazines; Pyridones; Ritonavir; Sulfonamides

2014
Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:2

    Topics: Adolescent; Carbamates; Child; Child, Preschool; Computer Simulation; Drug Dosage Calculations; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Models, Biological; Organophosphates; Prodrugs; Ritonavir; Sulfonamides

2014
The influence of gastric motility on the intraluminal behavior of fosamprenavir.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2020, Jan-15, Volume: 142

    Topics: Adult; Carbamates; Cross-Over Studies; Digestion; Duodenum; Female; Furans; Gastrointestinal Agents; Gastrointestinal Motility; Humans; Male; Middle Aged; Organophosphates; Stomach; Sulfonamides; Young Adult

2020

Other Studies

318 other study(ies) available for carbamates and amprenavir

ArticleYear
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
    The Journal of infectious diseases, 1995, Volume: 172, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Blood; Blood Proteins; Carbamates; Cattle; Fetus; Furans; HIV Protease Inhibitors; Humans; Kinetics; Molecular Structure; Orosomucoid; Protein Binding; Spectrophotometry, Ultraviolet; Sulfonamides

1995
In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease.
    Journal of virology, 1995, Volume: 69, Issue:9

    Topics: Amino Acid Sequence; Base Sequence; Carbamates; Cell Line; DNA Primers; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Molecular Structure; Mutagenesis, Site-Directed; Point Mutation; Polymerase Chain Reaction; Protein Conformation; Recombinant Proteins; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication

1995
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
    The Journal of infectious diseases, 1996, Volume: 173, Issue:6

    Topics: Antiviral Agents; Blood Proteins; Carbamates; Clinical Trials as Topic; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Orosomucoid; Protein Binding; Sulfonamides

1996
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
    The Journal of biological chemistry, 1996, Jul-26, Volume: 271, Issue:30

    Topics: Amino Acid Sequence; Binding Sites; Carbamates; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Indinavir; Isoquinolines; Kinetics; Models, Molecular; Molecular Sequence Data; Mutation; Oligopeptides; Pyridines; Quinolines; Saquinavir; Selection, Genetic; Substrate Specificity; Sulfonamides

1996
In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9.
    Rapid communications in mass spectrometry : RCM, 1996, Volume: 10, Issue:9

    Topics: Animals; Aroclors; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Macaca fascicularis; Mass Spectrometry; Rats; Rats, Sprague-Dawley; Species Specificity; Spectrophotometry, Ultraviolet; Subcellular Fractions; Sulfonamides

1996
Calculation of solvation and binding free energy differences between VX-478 and its analogs by free energy perturbation and AMSOL methods.
    Journal of computer-aided molecular design, 1996, Volume: 10, Issue:1

    Topics: Binding Sites; Carbamates; Computer Simulation; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Structure; Software; Solvents; Sulfonamides; Thermodynamics; Water

1996
Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity.
    The Journal of biological chemistry, 1996, Dec-13, Volume: 271, Issue:50

    Topics: Carbamates; Clinical Trials as Topic; Furans; Fusion Proteins, gag-pol; HIV Protease; HIV Protease Inhibitors; Humans; Hydrolysis; Indinavir; Kinetics; Mutagenesis; Ritonavir; Sulfonamides

1996
Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex.
    The Journal of biological chemistry, 1996, Dec-27, Volume: 271, Issue:52

    Topics: Antiviral Agents; Carbamates; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Kinetics; Mutagenesis; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Sulfonic Acids

1996
In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors.
    The Journal of infectious diseases, 1997, Volume: 175, Issue:5

    Topics: Anti-HIV Agents; Carbamates; Cell Line; Cells, Cultured; Ethylenes; Furans; HIV Protease Inhibitors; HIV Seronegativity; HIV-1; Humans; Indinavir; Kinetics; Lymphocytes; Orosomucoid; Ritonavir; Saquinavir; Sulfonamides; Urea; Virus Replication

1997
A molecular field-based similarity approach to pharmacophoric pattern recognition.
    Journal of molecular graphics & modelling, 1997, Volume: 15, Issue:2

    Topics: Carbamates; Computer Graphics; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Structure; Oligopeptides; Pattern Recognition, Automated; Sugar Alcohols; Sulfonamides; Valine

1997
A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.
    Biochemical and biophysical research communications, 1998, Jan-26, Volume: 242, Issue:3

    Topics: Binding Sites; Carbamates; Computer Simulation; Drug Design; Drug Resistance; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Molecular Conformation; Mutagenesis, Site-Directed; Protein Binding; Ritonavir; Sulfonamides

1998
Practical synthesis of (2s,3s)-3-amino-2-hydroxy-4-phenylbutyric acid, a key component of HIV protease inhibitors.
    Chemical & pharmaceutical bulletin, 1998, Volume: 46, Issue:4

    Topics: Anti-HIV Agents; Carbamates; Furans; HIV Protease Inhibitors; Nitriles; Oligopeptides; Phenylbutyrates; Stereoisomerism; Sulfonamides

1998
Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
    Journal of pharmaceutical sciences, 1998, Volume: 87, Issue:7

    Topics: Anti-HIV Agents; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Furans; HIV Protease Inhibitors; Humans; Isoenzymes; Microsomes, Liver; Mixed Function Oxygenases; Ritonavir; Saquinavir; Sulfonamides

1998
Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy.
    Nature medicine, 1998, Volume: 4, Issue:7

    Topics: Adult; Aged; Anti-HIV Agents; Carbamates; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Division; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ki-67 Antigen; Lymph Nodes; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides

1998
Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:9

    Topics: Anti-HIV Agents; Carbamates; Cell Line; Dideoxynucleosides; Drug Synergism; Furans; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides

1998
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
    AIDS (London, England), 1998, Sep-10, Volume: 12, Issue:13

    Topics: Amino Acid Substitution; Carbamates; Clinical Trials as Topic; Databases, Factual; DNA, Viral; Furans; Genetic Linkage; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Methionine; Nelfinavir; Phenotype; Polymerase Chain Reaction; Ritonavir; Saquinavir; Sulfonamides; Valine

1998
Phase III results of second-generation HIV protease inhibitor reported.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:11

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine

1998
The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir.
    Infectious diseases in obstetrics and gynecology, 1998, Volume: 6, Issue:6

    Topics: Carbamates; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Maternal-Fetal Exchange; Placenta; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Sulfonamides

1998
Updated data on amprenavir.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:5

    Topics: Adult; Carbamates; Child; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Semen; Sulfonamides; Viral Load

1999
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
    AIDS (London, England), 1999, May-07, Volume: 13, Issue:7

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Zidovudine

1999
Amprenavir approved for HIV treatment.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Jun-01, Volume: 56, Issue:11

    Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration

1999
Amprenavir: a new HIV protease inhibitor.
    The Medical letter on drugs and therapeutics, 1999, Jul-16, Volume: 41, Issue:1057

    Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Carbamates; Child; Clinical Trials as Topic; Cross Reactions; Diarrhea; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Exanthema; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nausea; Stevens-Johnson Syndrome; Sulfonamides

1999
Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
    Pharmaceutical research, 1999, Volume: 16, Issue:8

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autoradiography; Biological Transport; Caco-2 Cells; Carbamates; Cattle; Central Nervous System; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Male; Mice; Mice, Knockout; Ritonavir; Sulfonamides; Whole-Body Irradiation

1999
Inhibition of adipocyte differentiation by HIV protease inhibitors.
    The Journal of clinical endocrinology and metabolism, 1999, Volume: 84, Issue:11

    Topics: 3T3 Cells; Adipocytes; Adiponectin; Animals; Carbamates; Carrier Proteins; Cell Differentiation; Dose-Response Relationship, Drug; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Furans; Gene Expression; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Intercellular Signaling Peptides and Proteins; Lipoprotein Lipase; Mice; Myelin P2 Protein; Nelfinavir; Neoplasm Proteins; Nerve Tissue Proteins; Proteins; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Ritonavir; Stem Cells; Sulfonamides; Transcription Factors; Triglycerides; Tumor Suppressor Proteins

1999
Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
    Pharmaceutical research, 1999, Volume: 16, Issue:12

    Topics: Algorithms; Animals; Biological Availability; Caco-2 Cells; Calcium Channel Blockers; Carbamates; Cell Membrane Permeability; Chromatography, High Pressure Liquid; Dogs; Furans; HIV Protease Inhibitors; Humans; Permeability; Polyethylene Glycols; Solubility; Stimulation, Chemical; Sulfonamides; Verapamil; Vitamin E

1999
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    The Journal of clinical investigation, 2000, Volume: 105, Issue:6

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine

2000
Amprenavir study results released.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:12

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load; Zidovudine

1999
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.
    Journal of virology, 2000, Volume: 74, Issue:9

    Topics: Anti-HIV Agents; Carbamates; Drug Hypersensitivity; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Sulfonamides

2000
When to switch and what to switch to: strategic use of antiretroviral therapy.
    The AIDS reader, 2000, Volume: 10, Issue:3

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Mutation; Nelfinavir; Practice Guidelines as Topic; Pyrimidinones; Retroviridae; Retroviridae Infections; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors; Treatment Failure; Viral Load

2000
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
    Journal of chromatography. B, Biomedical sciences and applications, 2000, Mar-31, Volume: 740, Issue:1

    Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides

2000
Metabolic profile of protease inhibitors studied.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:9

    Topics: Adipose Tissue; Animals; Carbamates; Disease Models, Animal; Furans; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hyperglycemia; Hyperlipidemias; Lipid Metabolism; Mice; Randomized Controlled Trials as Topic; Retrospective Studies; Sulfonamides

1999
Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:6

    Topics: Anti-HIV Agents; Carbamates; Computer Simulation; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Furans; Humans; Monte Carlo Method; Sulfonamides

2000
[Second chance therapy. New protease inhibitor for salvage therapy].
    MMW Fortschritte der Medizin, 2000, Mar-13, Volume: 142 Suppl 1

    Topics: Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Salvage Therapy; Sulfonamides; Treatment Outcome

2000
Amprenavir approved.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:7

    Topics: Anti-HIV Agents; Carbamates; Controlled Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Sulfonamides; Treatment Outcome; United States; United States Food and Drug Administration

1999
Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.
    Journal of chromatography. B, Biomedical sciences and applications, 2000, May-26, Volume: 742, Issue:1

    Topics: Adult; Anti-HIV Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Male; Reproducibility of Results; Semen; Sensitivity and Specificity; Spectrometry, Fluorescence; Sulfonamides

2000
Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.
    AIDS (London, England), 2000, Jun-16, Volume: 14, Issue:9

    Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line, Transformed; Colonic Neoplasms; Drug Resistance, Multiple; Furans; Gene Expression Regulation, Neoplastic; HIV Protease Inhibitors; Humans; Indinavir; Ivermectin; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Tumor Cells, Cultured; Verapamil; Vinblastine

2000
Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.
    Journal of virology, 2000, Volume: 74, Issue:16

    Topics: Carbamates; Crystallography, X-Ray; Drug Resistance, Microbial; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Mutation; Protein Conformation; Saquinavir; Sulfonamides

2000
Mutation causes sensitivity.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:7

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Sulfonamides

2000
Simultaneous determination of the five HIV-protease inhibitors: amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography.
    Therapeutic drug monitoring, 2000, Volume: 22, Issue:4

    Topics: Carbamates; Chromatography, Liquid; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2000
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
    The Journal of infectious diseases, 2000, Volume: 182, Issue:3

    Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine

2000
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
    European journal of clinical pharmacology, 2000, Volume: 56, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Furans; Humans; Hydroxylation; Ketoconazole; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides; Triazolam

2000
Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice.
    The Journal of nutrition, 2000, Volume: 130, Issue:9

    Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Carbamates; Dietary Fats; Drug Interactions; Furans; HIV Protease Inhibitors; Indinavir; Injections, Subcutaneous; Insulin; Liver; Male; Mice; Mice, Inbred AKR; Nelfinavir; Saquinavir; Sulfonamides

2000
Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Amino Acid Sequence; Amino Acid Substitution; Carbamates; Codon; Drug Resistance, Microbial; Furans; Global Health; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Phylogeny; Ritonavir; Saquinavir; Sulfonamides

2000
Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
    AIDS (London, England), 2000, Aug-18, Volume: 14, Issue:12

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Child; Child, Preschool; Cyclopropanes; Delavirdine; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors

2000
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
    Antiviral research, 2000, Volume: 47, Issue:2

    Topics: Adipocytes; Animals; Azo Compounds; Bexarotene; Carbamates; Carrier Proteins; Cell Differentiation; Cells, Cultured; Coloring Agents; Fatty Acid-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Insulin; Lipolysis; Lipoprotein Lipase; Nelfinavir; Neoplasm Proteins; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Ritonavir; RNA, Messenger; Rosiglitazone; Saquinavir; Stem Cells; Sulfonamides; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides

2000
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:9

    Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides

2000
Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:11

    Topics: Carbamates; Drug Resistance, Microbial; Drug Resistance, Multiple; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Ritonavir; Saquinavir; Sulfonamides

2000
Warning for oral solution.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:9

    Topics: Administration, Oral; Carbamates; Chemistry, Pharmaceutical; Drug Labeling; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Pharmaceutical Vehicles; Propylene Glycol; Solutions; Sulfonamides

2000
Pharmacology and clinical experience with amprenavir.
    Expert opinion on investigational drugs, 2000, Volume: 9, Issue:2

    Topics: Animals; Antiretroviral Therapy, Highly Active; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Furans; HIV Protease Inhibitors; Humans; Sulfonamides

2000
[Hyperlipoproteineumia in HIV patients undergoing antiretroviral therapy: which risk is greater--pancreatitis or coronary disease?].
    Deutsche medizinische Wochenschrift (1946), 2000, Nov-24, Volume: 125, Issue:47

    Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Anti-HIV Agents; Carbamates; Coronary Disease; Dideoxynucleosides; Drug Therapy, Combination; Furans; Hepatitis B; HIV Protease Inhibitors; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pancreatitis; Risk Factors; Ritonavir; Sulfonamides

2000
The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.
    Pharmaceutical research, 2000, Volume: 17, Issue:10

    Topics: Acetamides; Albumins; Azepines; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Intestinal Absorption; Nelfinavir; Ritonavir; Solvents; Structure-Activity Relationship; Sulfonamides; Urea

2000
Raising levels of amprenavi.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:11

    Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Viral Load

2000
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
    The Journal of infectious diseases, 2001, Mar-01, Volume: 183, Issue:5

    Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine

2001
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
    AIDS (London, England), 2001, Mar-09, Volume: 15, Issue:4

    Topics: Animals; Astrocytes; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport, Active; Blood-Brain Barrier; Caco-2 Cells; Carbamates; Cattle; Cell Line, Transformed; Cells, Cultured; Coculture Techniques; Cyclosporins; Dibenzocycloheptenes; Endothelium, Vascular; Furans; HIV Protease Inhibitors; Humans; Indinavir; LLC-PK1 Cells; Multidrug Resistance-Associated Proteins; Probenecid; Quinolines; Rats; Rats, Wistar; Ritonavir; Sulfonamides; Swine; Verapamil

2001
Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2001, Volume: 29, Issue:5

    Topics: Animals; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Furans; HIV Protease Inhibitors; Humans; Intestinal Mucosa; Intestines; Liver; Male; Nelfinavir; Oxidoreductases, N-Demethylating; Rats; Rats, Wistar; Sulfonamides; Tumor Cells, Cultured

2001
Phase III trials for new PI.
    AIDS patient care and STDs, 2001, Volume: 15, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; Carbamates; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Furans; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Nelfinavir; Organophosphates; Prodrugs; Randomized Controlled Trials as Topic; Sulfonamides

2001
Effect of reduced-dose amprenavir in combination with lopinavir on plasma levels of amprenavir in patients infected with HIV.
    Clinical therapeutics, 2001, Volume: 23, Issue:3

    Topics: Adult; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Sulfonamides

2001
Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy.
    Journal of chromatography. A, 2001, Apr-20, Volume: 914, Issue:1-2

    Topics: Anti-HIV Agents; Carbamates; Chromatography, Liquid; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mass Spectrometry; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides

2001
Abacavir (1592) with protease inhibitors in potent antiretroviral activity.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides; Viral Load

1998
Double protease inhibitor regimens with amprenavir show promise.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:4

    Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Sulfonamides; Viral Load; Zidovudine

1998
Amprenavir made available through early access program.
    AIDS patient care and STDs, 1998, Volume: 12, Issue:12

    Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States

1998
NDA submitted for amprenavir.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:1

    Topics: Carbamates; Furans; HIV Protease Inhibitors; Humans; Investigational New Drug Application; Sulfonamides

1999
Agenerase shows promise in treatment-naïve and treatment-experienced HIV patients.
    AIDS patient care and STDs, 1999, Volume: 13, Issue:2

    Topics: Carbamates; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Sulfonamides

1999
Protease inhibitors and prevention of cross resistance.
    AIDS treatment news, 1995, Oct-06, Issue:no 232

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine

1995
New protease drug shows early promise.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1995

    Topics: Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV; HIV Protease Inhibitors; Humans; Sulfonamides

1995
Conference looks at HIV drug resistance.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1995, Volume: 9, Issue:9

    Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine

1995
ICAAC update.
    STEP perspective, 1996,Fall, Volume: 8, Issue:3

    Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load

1996
Pediatric trial of 141W94, Vertex protease inhibitor.
    AIDS treatment news, 1997, Jul-18, Issue:No 275

    Topics: Adolescent; Anti-HIV Agents; Carbamates; Child; Child, Preschool; Clinical Trials, Phase III as Topic; Furans; HIV Infections; Humans; Infant; Patient Selection; Sulfonamides; United States; Viral Load

1997
141 (Vertex-478).
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1997

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine

1997
Expanded access to experimental drugs: activists seek more open programs.
    AIDS treatment news, 1997, Nov-07, Issue:No 282

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dideoxynucleosides; Drug Industry; Furans; Health Services Accessibility; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Sulfonamides

1997
Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
    AIDS treatment news, 1997, Dec-05, Issue:No 284

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials, Phase II as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Multicenter Studies as Topic; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure

1997
What's new and what's next.
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1998, Volume: 10, Issue:1

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

1998
Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Carbamates; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

1998
New drugs: amprenavir and abacavir.
    TreatmentUpdate, 1998, Volume: 10, Issue:2

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine

1998
What's new, what's next?
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1998,Summer, Volume: 10, Issue:2

    Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Carbamates; Decision Making; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Patient Compliance; Saquinavir; Sulfonamides

1998
New drugs on the horizon.
    Project Inform perspective, 1998, Issue:24

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine

1998
New drugs in development.
    Project Inform perspective, 1998, Issue:25

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load

1998
Amprenavir (Agenerase) now available in expanded access.
    AIDS treatment news, 1998, Oct-02, Issue:No 304

    Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides

1998
Access to efavirenz and amprenavir.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1998, Volume: 12, Issue:10

    Topics: Alkynes; Benzoxazines; Carbamates; Cyclopropanes; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States

1998
Expanded access program begins.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Patient Selection; Sulfonamides; United States

1998
Glaxo Wellcome's two new drugs.
    Research initiative, treatment action : RITA, 1998, Volume: 4, Issue:7

    Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides

1998
What's new, what's next?
    Positive Directions news : a support and information network of people with HIV/AIDS, their families, friends and providers, 1999,Winter, Volume: 11, Issue:1

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

1999
Retrovirus conference report: three new agents to the rescue.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1999, Volume: 13, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Congresses as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Peptide Fragments; Pyrimidinones; Salvage Therapy; Sulfonamides; Viral Load; Virus Replication

1999
Antimicrobial agents and chemotherapy: highlights of the 38th Interscience Conference.
    The Body positive, 1998, Volume: 11, Issue:12

    Topics: Adenine; Antiviral Agents; Bacterial Vaccines; Carbamates; Congresses as Topic; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Pneumococcal Infections; Sulfonamides; Vaccination; Viral Load

1998
The new drugs and how to use them.
    The Hopkins HIV report : a bimonthly newsletter for healthcare providers, 1999, Volume: 11, Issue:1

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Sulfonamides

1999
Some existing drugs work on resistant HIV.
    AIDS alert, 2000, Volume: 15, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Dioxolanes; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Purine Nucleosides; Pyridines; Pyrones; Sulfonamides

2000
Study: new drug doesn't display cross-resistance.
    AIDS alert, 1999, Volume: 14, Issue:7

    Topics: Carbamates; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Salvage Therapy; Sulfonamides

1999
Amprenavir, new protease inhibitor, approved.
    AIDS treatment news, 1999, May-07, Issue:No 318

    Topics: Adolescent; Adult; Carbamates; Child; Child, Preschool; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States Food and Drug Administration

1999
Expanded access.
    Project Inform perspective, 1998, Issue:26

    Topics: Adenine; Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides

1998
Antivirals update.
    Project Inform perspective, 1998, Issue:26

    Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides

1998
Drug approval.
    AIDS policy & law, 1999, Apr-30, Volume: 14, Issue:8

    Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration

1999
Amprenavir (Agenerase) receives FDA approval. Food and Drug Administration.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1999, Volume: 12, Issue:2

    Topics: Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration

1999
Amprenavir (Agenerase).
    Research initiative, treatment action : RITA, 1999, Jul-01, Volume: 5, Issue:3

    Topics: Biological Availability; Carbamates; Clinical Trials as Topic; Diet; Drug Interactions; Drug Resistance, Microbial; Drug Storage; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Pharmacokinetics; Sulfonamides

1999
Expanded access.
    Project Inform perspective, 1999, Issue:27

    Topics: Adenine; Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; United States; United States Food and Drug Administration

1999
Amprenavir approved.
    STEP perspective, 1999,Summer, Volume: 99, Issue:2

    Topics: Anti-HIV Agents; Carbamates; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration

1999
New treatment options.
    The Body positive, 1999, Volume: 12, Issue:6

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load

1999
Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Newsline (People with AIDS Coalition of New York), 1998

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides

1998
New expanded access drugs for use in combination therapy.
    Newsline (People with AIDS Coalition of New York), 1998

    Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Child; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Pregnancy; Sulfonamides

1998
Amprenavir: a new protease inhibitor nears approval.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1999, Volume: 12, Issue:1

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sulfonamides

1999
New anti-HIV drugs in development.
    Project Inform perspective, 1999, Issue:28

    Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Capsules; Carbamates; Chemistry, Pharmaceutical; Didanosine; Drug Synergism; Drug Therapy, Combination; Drugs, Investigational; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Menorrhagia; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides

1999
Novel approaches for the treatment of HIV.
    Newsline (People with AIDS Coalition of New York), 1998

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genetic Therapy; Heterocyclic Compounds; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Oxazines; Receptors, Chemokine; Reverse Transcriptase Inhibitors; Sulfonamides; Zinc Fingers

1998
Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
    Newsline (People with AIDS Coalition of New York), 1998

    Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; Genetic Techniques; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load

1998
Moving forward: a treatment overview from the 12th World AIDS Conference.
    Newsline (People with AIDS Coalition of New York), 1998

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Furans; Health Services Accessibility; HIV Protease Inhibitors; Humans; Hydroxyurea; Lopinavir; Oxazines; Patient Care Planning; Pyrimidinones; Remission Induction; Reverse Transcriptase Inhibitors; Sulfonamides; Switzerland; Virus Replication

1998
[Determining resistance in HIV therapy. Careful interpretation only].
    MMW Fortschritte der Medizin, 2001, Apr-02, Volume: 143 Suppl 1

    Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Drug Resistance, Microbial; Furans; HIV; HIV Infections; Humans; Mutation; Sulfonamides

2001
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, May-05, Volume: 755, Issue:1-2

    Topics: Adult; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2001
Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Jun-15, Volume: 757, Issue:2

    Topics: Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Reference Standards; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides

2001
Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.
    Therapeutic drug monitoring, 2001, Volume: 23, Issue:4

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Delavirdine; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Mass Spectrometry; Nelfinavir; Nevirapine; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides

2001
High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid e
    Journal of chromatography. B, Biomedical sciences and applications, 2001, Jul-15, Volume: 758, Issue:2

    Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Nevirapine; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides

2001
Drifting agenda for federal treatment research.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 2001, Volume: 15, Issue:5

    Topics: Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; Financing, Government; Furans; HIV Infections; HIV Protease Inhibitors; National Institutes of Health (U.S.); Reverse Transcriptase Inhibitors; Sulfonamides; United States

2001
Effectors of HIV-1 protease peptidolytic activity.
    Biochemistry, 2001, Sep-18, Volume: 40, Issue:37

    Topics: Carbamates; DNA; Drug Interactions; Enzyme Activation; Fluorescent Dyes; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Ligands; Models, Chemical; Oligopeptides; Poly A; Polyelectrolytes; Polymers; Sodium Chloride; Sulfonamides

2001
Amping amprenavir with ritonavir.
    TreatmentUpdate, 2001,Spring, Volume: 12, Issue:12

    Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Viral Load

2001
Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.
    Therapeutic drug monitoring, 2001, Volume: 23, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Carbamates; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; HIV-1; Humans; Methadone; Reverse Transcriptase Inhibitors; Substance-Related Disorders; Sulfonamides

2001
Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Clinical laboratory, 2001, Volume: 47, Issue:9-10

    Topics: Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sulfonamides

2001
Resistant to everything.
    AIDS clinical care, 2001, Volume: 13, Issue:5

    Topics: Aged; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lopinavir; Male; Patient Compliance; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Viral Load

2001
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
    AIDS (London, England), 2001, Nov-23, Volume: 15, Issue:17

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load

2001
Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Dec-15, Volume: 33, Issue:12

    Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Microbial; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Sulfonamides; Viral Load

2001
Amprenavir (Agenerase).
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:1

    Topics: Carbamates; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Practice Guidelines as Topic; Sulfonamides

2000
In vitro activity of amprenavir against Pneumocystis carinii.
    International journal of antimicrobial agents, 2001, Volume: 18, Issue:3

    Topics: Animals; Antibiotics, Antitubercular; Carbamates; Cell Line; Dose-Response Relationship, Drug; Furans; Humans; Models, Animal; Pneumocystis; Rats; Sulfonamides

2001
Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.
    The Journal of biological chemistry, 2002, Feb-22, Volume: 277, Issue:8

    Topics: Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Carbamates; Cell Line; Cloning, Molecular; Drug Resistance, Microbial; Furans; Gene Products, gag; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Recombinant Proteins; Restriction Mapping; Sulfonamides

2002
Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:2

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Drug Therapy, Combination; Furans; HIV; HIV Infections; Humans; Ritonavir; RNA, Viral; Sulfonamides

2002
Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?
    AIDS (London, England), 2002, Jan-25, Volume: 16, Issue:2

    Topics: Carbamates; Drug Synergism; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Pilot Projects; Pyrimidinones; Ritonavir; Sulfonamides

2002
Central nervous system toxicity and amprenavir oral solution.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:1

    Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Sulfonamides

2002
Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2002, Jan-25, Volume: 766, Issue:2

    Topics: Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; HIV Protease Inhibitors; HIV-1; Humans; Male; Mass Spectrometry; Reference Standards; Reproducibility of Results; Semen; Sensitivity and Specificity; Sulfonamides

2002
In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    The Journal of pharmacy and pharmacology, 2002, Volume: 54, Issue:2

    Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Furans; HIV Protease Inhibitors; In Vitro Techniques; Indinavir; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides; Time Factors

2002
[Advances in the domain of HIV].
    Presse medicale (Paris, France : 1983), 2002, Jan-19, Volume: 31, Issue:2

    Topics: Anti-HIV Agents; Blood; Carbamates; Cerebrospinal Fluid; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genitalia; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Mutation; Phenotype; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; Sulfonamides; Time Factors; Viral Load

2002
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    AIDS (London, England), 2002, Mar-08, Volume: 16, Issue:4

    Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine

2002
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:2

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides

2002
Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
    The Journal of biological chemistry, 2002, May-31, Volume: 277, Issue:22

    Topics: Adipocytes; Animals; Animals, Newborn; Bone and Bones; Calcium; Carbamates; Cells, Cultured; Down-Regulation; Fats; Furans; Glycoproteins; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mesoderm; Nelfinavir; Osteoblasts; Osteoclasts; Osteoprotegerin; Pyrimidinones; Rats; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Ritonavir; Saquinavir; Skull; Stem Cells; Sulfonamides

2002
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, May-01, Volume: 34, Issue:9

    Topics: Amino Acid Substitution; Anti-HIV Agents; Asparagine; Carbamates; Drug Hypersensitivity; Furans; Gene Frequency; HIV; HIV Protease; Humans; Mutation; Serine; Sulfonamides

2002
Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.
    AIDS (London, England), 2002, May-03, Volume: 16, Issue:7

    Topics: Carbamates; Codon; Drug Resistance, Multiple, Viral; Furans; Genes, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Lopinavir; Mutation; Phenotype; Pyrimidinones; Recombination, Genetic; Sulfonamides; Virus Replication

2002
Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
    AIDS (London, England), 2002, Mar-29, Volume: 16, Issue:5

    Topics: Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Ritonavir; Salvage Therapy; Sulfonamides

2002
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
    AIDS (London, England), 2002, Mar-29, Volume: 16, Issue:5

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Delavirdine; Drug Synergism; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides

2002
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
    AIDS (London, England), 2002, Mar-29, Volume: 16, Issue:5

    Topics: Carbamates; Drug Evaluation; Furans; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2002
FDA approves new dosing for amprenavir and ritonavir combination.
    AIDS treatment news, 2002, Mar-08, Issue:378

    Topics: Carbamates; Drug Approval; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; United States; United States Food and Drug Administration

2002
New dosing regimen approved.
    AIDS patient care and STDs, 2002, Volume: 16, Issue:4

    Topics: Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides

2002
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
    Therapeutic drug monitoring, 2002, Volume: 24, Issue:3

    Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides

2002
Lipodystrophy update.
    Project Inform perspective, 2002, Issue:34

    Topics: Carbamates; Furans; Growth Hormone; HIV Infections; Humans; Lipodystrophy; Reverse Transcriptase Inhibitors; Sulfonamides; Surgery, Plastic

2002
GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
    Antimicrobial agents and chemotherapy, 2002, Volume: 46, Issue:7

    Topics: Acridines; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Carbamates; Furans; HIV Protease Inhibitors; Isoquinolines; Microdialysis; Sulfonamides; Tetrahydroisoquinolines

2002
Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
    Journal of virology, 2002, Volume: 76, Issue:15

    Topics: Binding Sites; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; gag Gene Products, Human Immunodeficiency Virus; Gene Products, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Substrate Specificity; Sulfonamides; Virus Replication

2002
Synthesis and antiviral activity of new anti-HIV amprenavir bioisosteres.
    Journal of medicinal chemistry, 2002, Jul-18, Volume: 45, Issue:15

    Topics: Anti-HIV Agents; Carbamates; Cell Line; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Virus Replication

2002
Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Protein science : a publication of the Protein Society, 2002, Volume: 11, Issue:8

    Topics: Binding Sites; Calorimetry; Carbamates; Drug Design; Drug Resistance, Viral; Escherichia coli; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Protein Binding; Sulfonamides; Thermodynamics; Urethane

2002
Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Aug-15, Volume: 35, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carbamates; Drug Administration Schedule; Female; Furans; Glucose; HIV Infections; Humans; Lipid Metabolism; Male; Pilot Projects; Prospective Studies; Sulfonamides

2002
Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor ab
    Journal of virology, 2002, Volume: 76, Issue:17

    Topics: Carbamates; Cell Line; Coculture Techniques; Drug Resistance, Viral; Furans; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nelfinavir; Protein Precursors; Sulfonamides; Virus Replication

2002
Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Antiviral chemistry & chemotherapy, 2002, Volume: 13, Issue:1

    Topics: Animals; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Furans; Half-Life; HIV Protease Inhibitors; Indinavir; Intestinal Mucosa; Liver; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides

2002
Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    European journal of biochemistry, 2002, Volume: 269, Issue:16

    Topics: Amino Acid Sequence; Amino Acid Substitution; Azepines; Binding Sites; Carbamates; Catalysis; Drug Resistance, Viral; Furans; Gene Products, gag; Genes, gag; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Protein Conformation; Substrate Specificity; Sulfonamides; Urea

2002
Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2002, Sep-15, Volume: 35, Issue:6

    Topics: Adult; Anti-HIV Agents; Carbamates; Chemistry, Pharmaceutical; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Organophosphates; Prodrugs; Ritonavir; Semen; Sulfonamides

2002
Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
    International journal of STD & AIDS, 2002, Volume: 13, Issue:9

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Cushing Syndrome; Diagnosis, Differential; Drug Therapy, Combination; Furans; HIV Protease Inhibitors; Humans; Lipodystrophy; Male; Megestrol Acetate; Reverse Transcriptase Inhibitors; Sulfonamides

2002
Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy.
    Journal of acquired immune deficiency syndromes (1999), 2002, Sep-01, Volume: 31, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Retrospective Studies; Salvage Therapy; Sulfonamides

2002
Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2002, Oct-15, Volume: 30, Issue:3

    Topics: Carbamates; Chromatography, Liquid; Furans; Gas Chromatography-Mass Spectrometry; HIV Protease Inhibitors; Indinavir; Nelfinavir; Ritonavir; Saquinavir; Sulfonamides

2002
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
    Journal of acquired immune deficiency syndromes (1999), 2002, Oct-01, Volume: 31, Issue:2

    Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine

2002
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
    AIDS research and human retroviruses, 2002, Sep-20, Volume: 18, Issue:14

    Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Retrospective Studies; RNA, Viral; Sulfonamides; Viremia

2002
FDA notifications. Agenerase product label changed.
    AIDS alert, 2002, Volume: 17, Issue:10

    Topics: Carbamates; Contraceptives, Oral, Hormonal; Drug Interactions; Drug Labeling; Furans; HIV Protease Inhibitors; Humans; Methadone; Sulfonamides; United States; United States Food and Drug Administration

2002
Using Agenerase. Nutritional considerations affect bioavailability of new P.I.
    Positive living (Los Angeles, Calif.), 1999, Volume: 8, Issue:6

    Topics: Biological Availability; Carbamates; Dietary Fats; Food-Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; Vitamin E

1999
Agenerase approved by FDA.
    Positive living (Los Angeles, Calif.), 1999, Volume: 8, Issue:4

    Topics: Carbamates; Drug Administration Schedule; Drug Approval; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides; United States; United States Food and Drug Administration

1999
Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.
    Biological & pharmaceutical bulletin, 2003, Volume: 26, Issue:2

    Topics: Animals; Carbamates; Drug Interactions; Furans; Indinavir; Infusions, Intravenous; Intestinal Absorption; Male; Microsomes, Liver; Nelfinavir; Rats; Rats, Wistar; Saquinavir; Sulfonamides

2003
Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation.
    Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:3

    Topics: Adult; Carbamates; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fetus; Furans; Humans; Infant; Infant, Newborn; Liver; Microsomes, Liver; Oxidation-Reduction; Protein Processing, Post-Translational; Sulfonamides

2003
Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans.
    Journal of medical microbiology, 2003, Volume: 52, Issue:Pt 3

    Topics: Antifungal Agents; Aspartic Acid Endopeptidases; Candida albicans; Carbamates; Cell Adhesion; Dose-Response Relationship, Drug; Furans; HIV Protease Inhibitors; Saquinavir; Sulfonamides

2003
Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.
    Journal of acquired immune deficiency syndromes (1999), 2003, Mar-01, Volume: 32, Issue:3

    Topics: Alkynes; Australia; Benzoxazines; Canada; Carbamates; Cyclopropanes; Europe; Furans; HIV Protease Inhibitors; Humans; International Cooperation; Laboratories; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sulfonamides; United States

2003
Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance.
    AIDS (London, England), 2003, May-02, Volume: 17, Issue:7

    Topics: Algorithms; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Phenotype; Pyrimidinones; Sulfonamides

2003
Genotype-phenotype discordance: the evolution in our understanding HIV-1 drug resistance.
    AIDS (London, England), 2003, May-02, Volume: 17, Issue:7

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Phenotype; Pyrimidinones; Sulfonamides

2003
Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.
    Therapeutic drug monitoring, 2003, Volume: 25, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; Heparin; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oxazines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides

2003
Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples.
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Atazanavir Sulfate; Carbamates; Drug Resistance, Multiple, Viral; Furans; HIV; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Sulfonamides

2003
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:7

    Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Resistance, Viral; Furans; Genes, Viral; HIV-1; Humans; Molecular Sequence Data; Oxazines; Phenotype; RNA-Directed DNA Polymerase; Sulfonamides

2003
HIV protease inhibitors acutely impair glucose-stimulated insulin release.
    Diabetes, 2003, Volume: 52, Issue:7

    Topics: Animals; Carbamates; Cells, Cultured; Furans; Glucose; HIV Protease Inhibitors; Indinavir; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Nelfinavir; Ritonavir; Sulfonamides

2003
Novel prodrug approach to amprenavir-based HIV-1 protease inhibitors via O-->N acyloxy migration of P1 moiety.
    Bioorganic & medicinal chemistry letters, 2003, Aug-04, Volume: 13, Issue:15

    Topics: Carbamates; Chemical Phenomena; Chemistry, Physical; Furans; HIV Protease Inhibitors; HIV-1; Hydrogen-Ion Concentration; Indicators and Reagents; Kinetics; Magnetic Resonance Spectroscopy; Prodrugs; Solubility; Structure-Activity Relationship; Sulfonamides

2003
Amprenavir (AGENERASE) oral solution: warning for some patients.
    AIDS treatment news, 2000, May-05, Issue:342

    Topics: Administration, Oral; Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Solutions; Sulfonamides

2000
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
    The Pediatric infectious disease journal, 2003, Volume: 22, Issue:7

    Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir

2003
The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells.
    The Journal of endocrinology, 2003, Volume: 178, Issue:3

    Topics: Biological Transport; Blotting, Western; Carbamates; Cell Membrane; Cells, Cultured; Deoxyglucose; Furans; Glucose Transporter Type 1; Glucose Transporter Type 3; Glucose Transporter Type 4; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Monosaccharide Transport Proteins; Muscle Proteins; Myoblasts; Nerve Tissue Proteins; Ritonavir; Saquinavir; Sulfonamides

2003
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
    Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:10

    Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; CD4-Positive T-Lymphocytes; Cell Line; Crystallography, X-Ray; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Sulfonamides; Virus Replication

2003
Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Antiviral therapy, 2003, Volume: 8, Issue:4

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome

2003
Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.
    AIDS (London, England), 2003, Oct-17, Volume: 17, Issue:15

    Topics: 3T3 Cells; Adipocytes; Animals; Carbamates; Cell Differentiation; Cell Line; Enzyme-Linked Immunosorbent Assay; Furans; HIV Protease Inhibitors; Indinavir; Lopinavir; Mice; Mice, Inbred Strains; Nelfinavir; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides

2003
Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003, Nov-01, Volume: 37, Issue:9

    Topics: Asparagine; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Isoleucine; Microbial Sensitivity Tests; Mutation; Serine; Sulfonamides; Valine

2003
Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.
    AIDS (London, England), 2003, Nov-21, Volume: 17, Issue:17

    Topics: 3T3 Cells; Adipocytes; Animals; Blotting, Western; Carbamates; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cell Nucleus; DNA-Binding Proteins; Furans; HIV Protease Inhibitors; Indinavir; Lamin Type A; Mice; Microscopy, Confocal; Nelfinavir; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcription Factors

2003
Potent antiviral activity of amprenavir in primary macrophages infected by human immunodeficiency virus.
    Antiviral research, 2004, Volume: 61, Issue:2

    Topics: Carbamates; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Macrophages; Sulfonamides; Virus Replication

2004
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
    AIDS (London, England), 2003, Dec-05, Volume: 17, Issue:18

    Topics: Adult; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Protease Inhibitors; HIV Seropositivity; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome

2003
Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis.
    International journal of STD & AIDS, 2004, Volume: 15, Issue:1

    Topics: Adult; AIDS-Associated Nephropathy; Antiretroviral Therapy, Highly Active; Carbamates; Drug Monitoring; Female; Furans; Humans; Lopinavir; Pyrimidinones; Renal Dialysis; Sulfonamides

2004
Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
    The Journal of antimicrobial chemotherapy, 2004, Volume: 53, Issue:3

    Topics: Carbamates; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyridines; Pyrimidinones; Pyrones; RNA, Viral; Sulfonamides

2004
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
    Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:3

    Topics: Animals; Biological Availability; Biotransformation; Caco-2 Cells; Carbamates; Dogs; Furans; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Male; Mass Spectrometry; Organophosphates; Prodrugs; Rats; Rats, Wistar; Sulfonamides

2004
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2004, Volume: 30, Issue:1

    Topics: Amino Acid Substitution; Carbamates; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Mutation; Mutation, Missense; Phenotype; Retrospective Studies; Salvage Therapy; Sulfonamides; Viral Load

2004
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients.
    AIDS (London, England), 2004, Jan-02, Volume: 18, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides

2004
Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
    AIDS (London, England), 2004, Jul-02, Volume: 18, Issue:10

    Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Carbamates; Child; Delavirdine; Drug Combinations; Furans; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Sulfonamides

2004
The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Drug metabolism and disposition: the biological fate of chemicals, 2004, Volume: 32, Issue:7

    Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbamates; Cell Line; Chromatography, Liquid; Furans; Indoles; Male; Mass Spectrometry; Mice; Mice, Knockout; Pyrroles; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Tetrahydroisoquinolines; Time Factors

2004
New approaches to the industrial synthesis of HIV protease inhibitors.
    Organic & biomolecular chemistry, 2004, Jul-21, Volume: 2, Issue:14

    Topics: Carbamates; Furans; HIV Protease Inhibitors; Molecular Conformation; Molecular Structure; Organophosphates; Sulfonamides

2004
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation, Missense; Ritonavir; Selection, Genetic; Sulfonamides; Treatment Failure; Viral Load; Viremia

2004
Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretro
    Journal of medical virology, 2004, Volume: 74, Issue:1

    Topics: Amino Acid Substitution; Carbamates; Cohort Studies; Drug Resistance, Multiple, Viral; Furans; Genes, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Multivariate Analysis; Mutation; Phenotype; Pyrimidinones; Regression Analysis; Sulfonamides

2004
Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.
    American journal of obstetrics and gynecology, 2004, Volume: 191, Issue:2

    Topics: Adult; Amniotic Fluid; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Maternal-Fetal Exchange; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Saquinavir; Sulfonamides

2004
Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
    HIV medicine, 2004, Volume: 5, Issue:5

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Directly Observed Therapy; Drug Administration Schedule; Female; Furans; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Ritonavir; Statistics, Nonparametric; Sulfonamides; Treatment Outcome; Viral Load

2004
Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.
    Journal of virology, 2004, Volume: 78, Issue:21

    Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Sulfonamides; Thermodynamics

2004
The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.
    Biophysical journal, 2005, Volume: 88, Issue:1

    Topics: Algorithms; Animals; Antibiotics, Antitubercular; Antidiarrheals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cell Line; Cell Membrane; Cytoplasm; Diffusion; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Furans; Kinetics; Liposomes; Loperamide; Models, Chemical; Protein Binding; Quinidine; Software; Sulfonamides; Time Factors; Xenobiotics

2005
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
    Biochemistry, 2004, Nov-16, Volume: 43, Issue:45

    Topics: Amino Acid Substitution; Binding, Competitive; Carbamates; Chromatography, Affinity; Chromatography, Gel; Dextrans; Dimerization; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrolysis; Kinetics; Protein Binding; Saquinavir; Spectrometry, Fluorescence; Substrate Specificity; Sulfonamides

2004
Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.
    The Journal of endocrinology, 2004, Volume: 183, Issue:3

    Topics: Carbamates; Cell Line; Furans; Glucose; HIV Protease Inhibitors; Humans; Indinavir; Insulin; Insulin Receptor Substrate Proteins; Insulin Secretion; Intracellular Signaling Peptides and Proteins; Islets of Langerhans; Nelfinavir; Phosphoproteins; Phosphorylation; Ritonavir; Saquinavir; Signal Transduction; Stimulation, Chemical; Sulfonamides; Time Factors

2004
Virtual screening of HIV-1 protease inhibitors against human cytomegalovirus protease using docking and molecular dynamics.
    AIDS (London, England), 2005, Mar-25, Volume: 19, Issue:5

    Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Binding Sites; Carbamates; Crystallography, X-Ray; Cytomegalovirus; Cytomegalovirus Infections; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Structure; Peptide Hydrolases; Sulfonamides

2005
Genotype dependent QSAR for HIV-1 protease inhibition.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Carbamates; Drug Resistance, Viral; Furans; Genotype; HIV Protease; HIV Protease Inhibitors; HIV-1; Mutation; Quantitative Structure-Activity Relationship; Sulfonamides; Thermodynamics

2005
Stimulation of intracellular Ca2+ elevation in neutrophils by thiol-oxidizing phenylarsine oxide.
    Biochemical pharmacology, 2005, Apr-15, Volume: 69, Issue:8

    Topics: Animals; Aorta, Abdominal; Aristolochic Acids; Arsenicals; Barium; Calcium; Calcium Signaling; Calcium-Transporting ATPases; Carbamates; Cell Membrane; Enzyme Inhibitors; Furans; Indazoles; Indoles; Male; Manganese; NADPH Oxidases; Neutrophils; Nitric Oxide; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Strontium; Sulfonamides

2005
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
    Therapeutic drug monitoring, 2005, Volume: 27, Issue:2

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides

2005
Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, May-02, Volume: 15, Issue:9

    Topics: Binding Sites; Carbamates; Drug Design; Furans; HIV Protease; HIV Protease Inhibitors; Kinetics; Lopinavir; Models, Molecular; Molecular Conformation; Pyrimidinones; Ritonavir; Sulfonamides

2005
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1.
    Journal of virology, 2005, Volume: 79, Issue:10

    Topics: Carbamates; Chronic Disease; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Nelfinavir; Retrospective Studies; Sulfonamides; Virus Replication; Withholding Treatment

2005
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
    AIDS (London, England), 2005, May-20, Volume: 19, Issue:8

    Topics: Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Multiple, Viral; Follow-Up Studies; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Treatment Failure; Viral Load

2005
A long-term survival case of small cell lung cancer in an HIV-infected patient.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed

2005
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
    European journal of clinical pharmacology, 2005, Volume: 61, Issue:7

    Topics: Adult; Atazanavir Sulfate; Carbamates; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Saquinavir; Sulfonamides

2005
Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.
    Journal of acquired immune deficiency syndromes (1999), 2005, Sep-01, Volume: 40, Issue:1

    Topics: Animals; Bradykinin; Carbamates; Coronary Vessels; Down-Regulation; Furans; HIV Protease Inhibitors; Indinavir; Methionine; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Nelfinavir; Nitric Oxide Synthase; Organ Culture Techniques; Ritonavir; RNA, Messenger; Saquinavir; Selenium Compounds; Sulfonamides; Superoxides; Swine; Vasomotor System

2005
The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.
    Pharmaceutical research, 2005, Volume: 22, Issue:10

    Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Carbamates; Cell Line; Cell Membrane Permeability; Computer Simulation; Dogs; Furans; Humans; Loperamide; Models, Biological; Pharmacokinetics; Quinidine; Reproducibility of Results; Sulfonamides; Tetrahydroisoquinolines

2005
Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal.
    Journal of acquired immune deficiency syndromes (1999), 2005, Dec-01, Volume: 40, Issue:4

    Topics: Adipocytes; Animals; Atazanavir Sulfate; Carbamates; Deoxyglucose; Dose-Response Relationship, Drug; Furans; Glucose; Glucose Clamp Technique; HIV Protease Inhibitors; Infusions, Intravenous; Insulin Resistance; Lopinavir; Male; Models, Animal; Muscle, Skeletal; Myocardium; Oligopeptides; Pyridines; Pyrimidinones; Rats; Ritonavir; Sulfonamides

2005
A monolithic-phase based on-line extraction approach for determination of pharmaceutical components in human plasma by HPLC-MS/MS and a comparison with liquid-liquid extraction.
    Journal of pharmaceutical and biomedical analysis, 2006, Feb-24, Volume: 40, Issue:3

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Furans; Humans; Mass Spectrometry; Oligopeptides; Online Systems; Pharmaceutical Preparations; Pyridines; Quality Control; Reference Standards; Solutions; Sulfonamides

2006
Estrogen receptor-alpha mediates gender differences in atherosclerosis induced by HIV protease inhibitors.
    The Journal of biological chemistry, 2006, Jan-20, Volume: 281, Issue:3

    Topics: Animals; Atherosclerosis; Carbamates; Cholesterol; Estrogen Receptor alpha; Female; Furans; HIV Protease Inhibitors; Male; Mice; Mice, Knockout; Receptors, LDL; Sex Characteristics; Sulfonamides

2006
Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations.
    AIDS (London, England), 2006, Jan-02, Volume: 20, Issue:1

    Topics: Adult; Antiretroviral Therapy, Highly Active; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mutation; Organophosphates; Prodrugs; Sulfonamides

2006
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2006, Jan-01, Volume: 41, Issue:1

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia

2006
Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir.
    Journal of pharmaceutical sciences, 2006, Volume: 95, Issue:2

    Topics: Adult; Caco-2 Cells; Carbamates; Chemistry, Pharmaceutical; Excipients; Fasting; Female; Furans; Humans; In Vitro Techniques; Intestinal Absorption; Male; Permeability; Pharmaceutical Preparations; Sulfonamides

2006
Determination of amprenavir total and unbound concentrations in plasma by high-performance liquid chromatography and ultrafiltration.
    Therapeutic drug monitoring, 2006, Volume: 28, Issue:1

    Topics: Area Under Curve; Carbamates; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Furans; HIV Protease Inhibitors; Humans; Protein Binding; Sulfonamides; Ultrafiltration

2006
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
    Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:1

    Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Furans; HIV Protease Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Indinavir; Isoenzymes; Kinetics; Nelfinavir; Recombinant Proteins; Ritonavir; Saquinavir; Sulfonamides; Testosterone

2006
Gated binding of ligands to HIV-1 protease: Brownian dynamics simulations in a coarse-grained model.
    Biophysical journal, 2006, Jun-01, Volume: 90, Issue:11

    Topics: Carbamates; Computer Simulation; Enzyme Activation; Furans; HIV Protease; HIV Protease Inhibitors; Indinavir; Ligands; Models, Molecular; Mutation; Saquinavir; Sulfonamides

2006
Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease.
    The Journal of general virology, 2006, Volume: 87, Issue:Pt 5

    Topics: Amino Acid Sequence; Animals; Carbamates; Escherichia coli; Furans; Gene Products, gag; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Leukemia Virus, Murine; Mice; Molecular Sequence Data; NIH 3T3 Cells; Oligopeptides; Peptide Hydrolases; Recombinant Proteins; Species Specificity; Sulfonamides

2006
Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
    AIDS (London, England), 2006, Apr-24, Volume: 20, Issue:7

    Topics: Carbamates; Codon; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Mutation; Nelfinavir; Phenotype; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides

2006
Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics.
    Journal of acquired immune deficiency syndromes (1999), 2006, Volume: 42, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Carbamates; Diarrhea; Drug Administration Schedule; Drug Combinations; Esomeprazole; Female; Furans; Headache; Humans; Male; Middle Aged; Nausea; Organophosphates; Ritonavir; Sulfonamides

2006
Amprenavir-induced maculopapular exanthem followed by desensitization in a patient with late-stage human immunodeficiency virus.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2006, Volume: 96, Issue:4

    Topics: Adult; Carbamates; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Sulfonamides

2006
Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation.
    Transplantation proceedings, 2006, Volume: 38, Issue:4

    Topics: Adult; Anti-HIV Agents; Carbamates; Furans; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Metabolic Clearance Rate; Middle Aged; Organophosphates; Sulfonamides; Treatment Outcome

2006
[Effects of various HIV protease inhibitors on function of rat insulinoma cells].
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2006, Volume: 35, Issue:3

    Topics: Animals; Carbamates; Furans; HIV Protease Inhibitors; Insulin; Insulin Secretion; Insulinoma; Islets of Langerhans; Pancreatic Neoplasms; Rats; Ritonavir; Sulfonamides

2006
A novel approach for in-process monitoring and managing cross-contamination in a high-throughput high-performance liquid chromatography assay with tandem mass spectrometric detection.
    Rapid communications in mass spectrometry : RCM, 2006, Volume: 20, Issue:14

    Topics: Biomarkers; Carbamates; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Drug Contamination; Furans; Humans; Lopinavir; Pyrimidinones; Quality Control; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Tandem Mass Spectrometry

2006
Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations.
    Journal of molecular modeling, 2007, Volume: 13, Issue:2

    Topics: Amino Acid Substitution; Aspartic Acid; Carbamates; Drug Resistance, Viral; Furans; Glutamic Acid; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Protein Binding; Sulfonamides; Thermodynamics

2007
New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
    Bioorganic & medicinal chemistry letters, 2006, Oct-01, Volume: 16, Issue:19

    Topics: Carbamates; Furans; HIV Protease Inhibitors; Humans; Molecular Mimicry; Morpholines; Peptides, Cyclic; Structure-Activity Relationship; Sulfonamides

2006
Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Jan-01, Volume: 845, Issue:1

    Topics: Atazanavir Sulfate; Calibration; Carbamates; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Fluorescence; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Sulfonamides; Ultraviolet Rays

2007
An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Apr-01, Volume: 848, Issue:2

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Spectrophotometry, Ultraviolet; Sulfonamides

2007
A combined empirical and mechanistic codon model.
    Molecular biology and evolution, 2007, Volume: 24, Issue:2

    Topics: Amino Acid Substitution; Animals; Anti-HIV Agents; Carbamates; Chloroplasts; Codon; Drug Resistance, Viral; Evolution, Molecular; Furans; Genes, Mitochondrial; Genes, Viral; HIV Infections; HIV Protease; HIV-1; Humans; Markov Chains; Models, Genetic; Models, Statistical; Mutation; Selection, Genetic; Sulfonamides

2007
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Amino Acid Sequence; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Indinavir; Molecular Sequence Data; Mutation; Nelfinavir; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides

2007
P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.
    Biochemistry, 2006, Dec-26, Volume: 45, Issue:51

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Biological Transport, Active; Carbamates; Cell Line; Cell Membrane Permeability; Dogs; Furans; Humans; Loperamide; Protein Binding; Quinidine; Signal Transduction; Substrate Specificity; Sulfonamides

2006
In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation.
    International journal of pharmaceutics, 2007, May-24, Volume: 336, Issue:2

    Topics: Alkaline Phosphatase; Biological Transport; Caco-2 Cells; Carbamates; Chromatography, High Pressure Liquid; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Intestinal Absorption; Intestinal Secretions; Organophosphates; Permeability; Phosphates; Phosphorylation; Prodrugs; Solubility; Sulfonamides

2007
High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.
    Journal of pharmaceutical and biomedical analysis, 2007, Mar-12, Volume: 43, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Molecular Structure; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Ritonavir; Saquinavir; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Sulfonamides; Time Factors

2007
Ligand configurational entropy and protein binding.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Jan-30, Volume: 104, Issue:5

    Topics: Algorithms; Anti-HIV Agents; Carbamates; Drug Design; Entropy; Furans; HIV Protease; Ligands; Models, Chemical; Models, Statistical; Molecular Conformation; Protein Binding; Protein Conformation; Proteins; Sulfonamides; Thermodynamics

2007
Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:5

    Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Male; Middle Aged; Models, Biological; Sulfonamides

2007
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
    Journal of medicinal chemistry, 2007, Mar-22, Volume: 50, Issue:6

    Topics: Binding Sites; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Models, Molecular; Mutation; Protein Binding; Protein Conformation; Sulfonamides; Thermodynamics

2007
Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    AIDS (London, England), 2007, May-31, Volume: 21, Issue:9

    Topics: Carbamates; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sulfonamides; Treatment Failure; Viral Load

2007
Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.
    AIDS (London, England), 2007, Jul-11, Volume: 21, Issue:11

    Topics: Adenine; Adult; Age Factors; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; Carbamates; Creatinine; Didanosine; Drug Interactions; Female; Furans; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Linear Models; Male; Middle Aged; Organophosphonates; Sulfonamides; Tenofovir; Time Factors

2007
Development and evaluation of an immunoassay for the monitoring of the anti-HIV drug amprenavir.
    Journal of immunological methods, 2007, Aug-31, Volume: 325, Issue:1-2

    Topics: Adult; Animals; Anti-HIV Agents; Antibodies; Carbamates; Chromatography, High Pressure Liquid; Cross Reactions; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Furans; Humans; Immune Sera; Molecular Structure; Organophosphates; Ovalbumin; Rabbits; Reproducibility of Results; Serum Albumin, Bovine; Sulfonamides; Vaccination

2007
Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
    The Journal of antimicrobial chemotherapy, 2007, Volume: 60, Issue:4

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Attention; Bilirubin; Carbamates; Chromatography, High Pressure Liquid; Female; Furans; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Organophosphates; Plasma; Ritonavir; Sulfonamides; Time Factors

2007
Liver function parameters in HIV/HCV co-infected patients treated with amprenavir and ritonavir and correlation with plasma levels.
    The new microbiologica, 2007, Volume: 30, Issue:3

    Topics: Adult; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Furans; Hepacivirus; Hepatitis B virus; Hepatitis C, Chronic; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Middle Aged; Ritonavir; Sulfonamides; Treatment Outcome

2007
Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.
    Cancer research, 2007, Oct-01, Volume: 67, Issue:19

    Topics: Androgens; Animals; Apoptosis; Calpain; Carbamates; Cell Line, Tumor; Dipeptides; Enzyme Activation; Furans; Humans; Ionomycin; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Sulfonamides; Transcriptional Activation; Transfection; Transplantation, Heterologous

2007
Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line; Cell Membrane; Digoxin; Dogs; Furans; Kinetics; Loperamide; Quinidine; Sulfonamides

2008
[Pharmacokinetics of amprenavir in HIV-1 patients with renal insufficiency].
    Medecine et maladies infectieuses, 2007, Volume: 37, Issue:12

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Carbamates; Female; Furans; Humans; Kidney Function Tests; Male; Middle Aged; Renal Insufficiency; Sulfonamides

2007
In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:3

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Boron Compounds; Carbamates; Carbon Radioisotopes; Cyclosporine; Drug Interactions; Fluorescent Dyes; Furans; Humans; LLC-PK1 Cells; Positron-Emission Tomography; Quinidine; Quinine; Rats; Sulfonamides; Swine; Verapamil

2008
Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
    AIDS (London, England), 2008, Jan-30, Volume: 22, Issue:3

    Topics: Carbamates; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome

2008
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
    Fundamental & clinical pharmacology, 2008, Volume: 22, Issue:1

    Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides

2008
Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008, Mar-01, Volume: 863, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Monitoring; Feasibility Studies; Furans; Humans; Molecular Structure; Nevirapine; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrophotometry, Ultraviolet; Stavudine; Sulfonamides

2008
[Plasma levels following the switch from amprenavir to fosamprenavir in HIV-infected patients under antiretroviral treatment with lopinavir/ritonavir].
    Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26, Issue:3

    Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides

2008
HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
    Journal of the American Chemical Society, 2008, May-14, Volume: 130, Issue:19

    Topics: Algorithms; Carbamates; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Structure-Activity Relationship; Sulfonamides

2008
Same patient, new stone composition: amprenavir urinary stone.
    Antiviral therapy, 2008, Volume: 13, Issue:5

    Topics: Adult; Anti-HIV Agents; Carbamates; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Urinary Calculi

2008
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:12

    Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides

2008
Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
    Journal of medicinal chemistry, 2008, Oct-23, Volume: 51, Issue:20

    Topics: Binding Sites; Carbamates; Darunavir; Furans; HIV Protease Inhibitors; HIV-1; Kinetics; Models, Molecular; Molecular Structure; Sulfonamides

2008
Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Proteins, 2009, May-15, Volume: 75, Issue:3

    Topics: Atazanavir Sulfate; Binding Sites; Binding, Competitive; Calorimetry, Differential Scanning; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Kinetics; Lopinavir; Models, Molecular; Molecular Structure; Mutation; Nelfinavir; Oligopeptides; Pepsin A; Protein Binding; Protein Structure, Tertiary; Pyridines; Pyrimidinones; Pyrones; Ritonavir; Saquinavir; Sulfonamides

2009
Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.
    Clinical chemistry, 2009, Volume: 55, Issue:1

    Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Furans; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sensitivity and Specificity; Solid Phase Extraction; Sulfonamides

2009
PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Journal of medical virology, 2008, Volume: 80, Issue:12

    Topics: Carbamates; Catalytic Domain; Cells, Cultured; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Models, Molecular; Mutagenesis, Site-Directed; Mutation, Missense; Protein Structure, Tertiary; Sulfonamides

2008
Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Journal of virology, 2009, Volume: 83, Issue:7

    Topics: Amino Acid Sequence; Carbamates; Cell Line; Drug Resistance, Viral; Furans; gag Gene Products, Human Immunodeficiency Virus; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation, Missense; Sulfonamides; Virus Replication

2009
Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Biochemical and biophysical research communications, 2009, Nov-13, Volume: 389, Issue:2

    Topics: Asparagine; Aspartic Acid; Carbamates; Catalytic Domain; Crystallography, X-Ray; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Hydrogen Bonding; Mutation; Nelfinavir; Sulfonamides

2009
HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
    Gastroenterology, 2010, Volume: 138, Issue:1

    Topics: Animals; Apoptosis; Carbamates; Cell Line; Cell Membrane Permeability; Endoplasmic Reticulum; Furans; HIV Infections; HIV Protease Inhibitors; Intestinal Mucosa; Lopinavir; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Pyrimidinones; Ritonavir; Stress, Physiological; Sulfonamides; Transcription Factor CHOP

2010
Multiple effects of amprenavir against Candida albicans.
    FEMS yeast research, 2010, Volume: 10, Issue:2

    Topics: Aspartic Acid Endopeptidases; Biofilms; Blood; Candida albicans; Candidiasis; Carbamates; Culture Media; Fungal Proteins; Fungemia; Furans; HIV Protease Inhibitors; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Sulfonamides

2010
Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease.
    Journal of molecular modeling, 2010, Volume: 16, Issue:10

    Topics: Amino Acid Substitution; Binding Sites; Carbamates; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; Ligands; Models, Molecular; Mutation; Protein Structure, Tertiary; Ritonavir; Sulfonamides

2010
Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia.
    Archives of toxicology, 2010, Volume: 84, Issue:4

    Topics: Animals; Atazanavir Sulfate; Carbamates; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; HIV Protease Inhibitors; Hyperlipidemias; Male; Oligonucleotide Array Sequence Analysis; Oligopeptides; Proteasome Endopeptidase Complex; Pyridines; Rats; Rats, Sprague-Dawley; Ritonavir; Sulfonamides

2010
Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.
    Biopharmaceutics & drug disposition, 2010, Volume: 31, Issue:2-3

    Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cells, Cultured; Fluoresceins; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Indinavir; Liver; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nelfinavir; Rats; Rats, Wistar; Ritonavir; Saquinavir; Sulfonamides

2010
Effect of the HIV protease inhibitor amprenavir on the growth and differentiation of primary gingival epithelium.
    Antiviral therapy, 2010, Volume: 15, Issue:2

    Topics: 3T3 Cells; Animals; Antiretroviral Therapy, Highly Active; Carbamates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Epithelium; Fibroblasts; Furans; Gingiva; HIV Protease Inhibitors; Humans; Keratinocytes; Mice; Organ Specificity; Sulfonamides

2010
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Antiviral therapy, 2010, Volume: 15, Issue:3

    Topics: Atazanavir Sulfate; Carbamates; Cell Line; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Phenotype; Pyridines; Recombination, Genetic; Sulfonamides; Treatment Failure

2010
Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling.
    Biopharmaceutics & drug disposition, 2010, Volume: 31, Issue:5-6

    Topics: Adrenergic beta-Antagonists; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Drug Interactions; Furans; Intestinal Absorption; Ketoconazole; Male; Perfusion; Polyethylene Glycols; Rats; Rats, Wistar; Splanchnic Circulation; Sulfonamides; Verapamil; Vitamin E

2010
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Archives of internal medicine, 2010, Jul-26, Volume: 170, Issue:14

    Topics: Adult; Anti-HIV Agents; Carbamates; Case-Control Studies; Cohort Studies; Confidence Intervals; Dideoxynucleosides; Female; France; Furans; HIV Infections; Hospitals, Isolation; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Organophosphates; Regression Analysis; Risk; Ritonavir; Sulfonamides

2010
Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
    The FEBS journal, 2010, Volume: 277, Issue:18

    Topics: Amino Acid Substitution; Carbamates; Crystallography, X-Ray; Dimerization; Drug Resistance, Multiple, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrophobic and Hydrophilic Interactions; Kinetics; Molecular Conformation; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Saquinavir; Sulfonamides

2010
HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
    Journal of molecular and cellular cardiology, 2010, Volume: 49, Issue:5

    Topics: Action Potentials; Animals; Carbamates; Chloride Channels; Furans; HIV Integrase Inhibitors; HIV Protease Inhibitors; Ion Channel Gating; Lopinavir; Membrane Potential, Mitochondrial; Mitochondria; Myocytes, Cardiac; Nelfinavir; Pyrimidinones; Pyrrolidinones; Rabbits; Raltegravir Potassium; Reactive Oxygen Species; Ritonavir; Sulfonamides; Time Factors

2010
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11

    Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides

2010
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.
    ChemMedChem, 2010, Nov-08, Volume: 5, Issue:11

    Topics: Carbamates; Crystallography, X-Ray; Darunavir; Dimerization; Drug Design; Drug Resistance, Multiple, Viral; Furans; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Proteins; Structure-Activity Relationship; Sulfonamides

2010
Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.
    Circulation, 2010, Nov-09, Volume: 122, Issue:19

    Topics: Animals; Animals, Newborn; Antiretroviral Therapy, Highly Active; Antiviral Agents; Blood Pressure; Carbamates; Cell Division; Furans; Hemodynamics; HIV Protease Inhibitors; Hypertension, Pulmonary; Hypoxia; Male; Monocrotaline; Nelfinavir; Pulmonary Artery; Rats; Rats, Wistar; Ritonavir; Sulfonamides

2010
Simultaneous bioanalysis of a phosphate prodrug and its parent compound using a multiplexed LC-MS method.
    Bioanalysis, 2010, Volume: 2, Issue:4

    Topics: Animals; Carbamates; Chromatography, Liquid; Drug Stability; Furans; Hydrophobic and Hydrophilic Interactions; Male; Mass Spectrometry; Organophosphates; Phosphates; Prodrugs; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors

2010
Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4

    Topics: Animals; Carbamates; Cell Line; Chlorocebus aethiops; COS Cells; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Pyrans; Sulfonamides

2011
Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Apr-05, Volume: 108, Issue:14

    Topics: Animals; Antiviral Agents; Autoradiography; beta-Galactosidase; Carbamates; Cell Line, Tumor; Cell Survival; Chickens; Dihydroorotate Dehydrogenase; DNA Primers; Furans; Humans; Indoles; Lamivudine; Mammals; Nevirapine; Oxadiazoles; Oxidoreductases Acting on CH-CH Group Donors; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Species Specificity; Sulfonamides; Time Factors; Virus Replication; Viruses

2011
In vitro activity of antiretroviral drugs against Plasmodium falciparum.
    Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:11

    Topics: Alkynes; Animals; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Carbamates; Cyclopropanes; Darunavir; Furans; Lopinavir; Nelfinavir; Nevirapine; Plasmodium falciparum; Pyridines; Pyrones; Ritonavir; Saquinavir; Sulfonamides

2011
Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.
    The journal of physical chemistry. B, 2011, Oct-20, Volume: 115, Issue:41

    Topics: Carbamates; Entropy; Furans; HIV Protease; HIV-1; Ligands; Molecular Dynamics Simulation; Nelfinavir; Protease Inhibitors; Protein Binding; Sulfonamides

2011
Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease.
    The FEBS journal, 2011, Volume: 278, Issue:22

    Topics: Animals; Binding Sites; Carbamates; Crystallography, X-Ray; Dimerization; Furans; Mice; Models, Molecular; Pepstatins; Peptide Hydrolases; Protease Inhibitors; Protein Binding; Protein Conformation; Sulfonamides; Xenotropic murine leukemia virus-related virus

2011
Fitting the elementary rate constants of the P-gp transporter network in the hMDR1-MDCK confluent cell monolayer using a particle swarm algorithm.
    PloS one, 2011, Volume: 6, Issue:10

    Topics: Adenosine Triphosphate; Algorithms; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carbamates; Cell Line; Digoxin; Dogs; Furans; Humans; Hydrolysis; Kinetics; Loperamide; Sulfonamides

2011
Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study.
    Hormone research in paediatrics, 2011, Volume: 76, Issue:6

    Topics: Adolescent; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Child; Cohort Studies; Cross-Sectional Studies; Female; Furans; Glucose Intolerance; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Male; Obesity; Prevalence; Prospective Studies; Puberty; Sulfonamides; United States

2011
Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.
    Pharmaceutical research, 2012, Volume: 29, Issue:4

    Topics: Antiviral Agents; Atazanavir Sulfate; Carbamates; Carboxylic Ester Hydrolases; Drug Interactions; Furans; Humans; Kinetics; Models, Molecular; Nelfinavir; Oligopeptides; Protease Inhibitors; Pyridines; Quantitative Structure-Activity Relationship; Ritonavir; Saquinavir; Sulfonamides

2012
Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
    Protein science : a publication of the Protein Society, 2012, Volume: 21, Issue:3

    Topics: Amino Acid Sequence; Binding Sites; Carbamates; Crystallography, X-Ray; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Kinetics; Saquinavir; Sulfonamides

2012
Therapeutic amprenavir concentrations in cerebrospinal fluid.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:4

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Male; Middle Aged; Sulfonamides; Tandem Mass Spectrometry

2012
Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Bioorganic & medicinal chemistry letters, 2012, Mar-01, Volume: 22, Issue:5

    Topics: Carbamates; Catalytic Domain; Cell Line; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Sulfonamides

2012
Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:5

    Topics: Amino Acid Substitution; Atazanavir Sulfate; Carbamates; Drug Resistance, Viral; Furans; HEK293 Cells; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Oligopeptides; Open Reading Frames; Plasmids; Polymorphism, Genetic; Pyridines; Sulfonamides; Transfection

2012
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir.
    Journal of computer-aided molecular design, 2012, Volume: 26, Issue:2

    Topics: Amino Acids; Carbamates; Catalytic Domain; Computer Simulation; Drug Resistance; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Protein Binding; Sulfonamides; Thermodynamics

2012
Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.
    Methods in enzymology, 2012, Volume: 509

    Topics: Anti-HIV Agents; Blood-Brain Barrier; Brain; Cadmium Compounds; Carbamates; Cell Survival; Cells, Cultured; Electric Impedance; Endothelial Cells; Furans; Gene Expression; HIV Core Protein p24; HIV Long Terminal Repeat; HIV-1; Humans; Leukocytes, Mononuclear; Microvessels; Nanoconjugates; Particle Size; Primary Cell Culture; Quantum Dots; Selenium Compounds; Sulfates; Sulfonamides; Transferrin; Zinc Sulfate

2012
Role of FAP48 in HIV-associated lipodystrophy.
    Journal of cellular biochemistry, 2012, Volume: 113, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Adipocytes; Alkynes; Animals; Antiretroviral Therapy, Highly Active; Benzoxazines; Calcineurin; Carbamates; Cell Differentiation; Cell Line; Cyclopropanes; Furans; Gene Expression; Glucocorticoids; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Mice; Saquinavir; Signal Transduction; Stavudine; Sulfonamides; Transfection

2012
Molecular and enzymatic characterization of XMRV protease by a cell-free proteolytic analysis.
    Journal of proteomics, 2012, Aug-03, Volume: 75, Issue:15

    Topics: Animals; bcl-2-Associated X Protein; Carbamates; Cell Line, Tumor; Cell-Free System; Furans; HIV Protease Inhibitors; Humans; Mice; Peptide Hydrolases; Proteolysis; PTEN Phosphohydrolase; Substrate Specificity; Sulfonamides; Viral Proteins; Xenotropic murine leukemia virus-related virus

2012
NMR study of xenotropic murine leukemia virus-related virus protease in a complex with amprenavir.
    Biochemical and biophysical research communications, 2012, Aug-24, Volume: 425, Issue:2

    Topics: Carbamates; Drug Discovery; Furans; HIV Protease Inhibitors; HIV-1; Nuclear Magnetic Resonance, Biomolecular; Peptide Hydrolases; Protein Structure, Secondary; Sulfonamides; Viral Nonstructural Proteins; Xenotropic murine leukemia virus-related virus

2012
Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts.
    Journal of cellular physiology, 2013, Volume: 228, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Furans; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Sulfonamides; Xenograft Model Antitumor Assays

2013
Interaction between HIV protease inhibitors (PIs) and hepatic transporters in sandwich cultured human hepatocytes: implication for PI-based DDIs.
    Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:3

    Topics: Carbamates; Cells, Cultured; Drug Interactions; Furans; Hepatocytes; HIV Protease Inhibitors; Humans; Lopinavir; Nelfinavir; Organic Anion Transporters; Ritonavir; Sulfonamides

2013
Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
    Journal of virology, 2013, Volume: 87, Issue:8

    Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV-1; Humans; Kinetics; Models, Molecular; Mutant Proteins; Mutation, Missense; Oligopeptides; Point Mutation; Protein Binding; Protein Conformation; Pyridines; Sulfonamides; Thermodynamics

2013
GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5

    Topics: Amino Acid Sequence; Atazanavir Sulfate; Binding Sites; Carbamates; Cell Line, Tumor; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Lopinavir; Molecular Docking Simulation; Molecular Sequence Data; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Structure-Activity Relationship; Sulfonamides; T-Lymphocytes; Virus Replication

2013
Pregnane X receptor mediates dyslipidemia induced by the HIV protease inhibitor amprenavir in mice.
    Molecular pharmacology, 2013, Volume: 83, Issue:6

    Topics: Animals; Binding Sites; Carbamates; Cell Line; Dyslipidemias; Furans; Gene Expression; HIV Protease Inhibitors; Humans; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Docking Simulation; Pregnane X Receptor; Receptors, Steroid; Sulfonamides

2013
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
    Journal of medicinal chemistry, 2013, May-23, Volume: 56, Issue:10

    Topics: Binding Sites; Calorimetry, Differential Scanning; Carbamates; Crystallization; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; Escherichia coli; Furans; Genes, Synthetic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Pyrrolidinones; Structure-Activity Relationship; Sulfonamides

2013
NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations.
    Computer methods and programs in biomedicine, 2013, Volume: 111, Issue:2

    Topics: Algorithms; Anti-HIV Agents; Bayes Theorem; Carbamates; Clinical Trials as Topic; Drug Monitoring; Furans; HIV Infections; Humans; Likelihood Functions; Models, Statistical; Reproducibility of Results; Software; Sulfonamides

2013
Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design.
    Journal of medicinal chemistry, 2013, Jul-11, Volume: 56, Issue:13

    Topics: Carbamates; Catalytic Domain; Crystallography, X-Ray; Drug Design; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Models, Molecular; Molecular Structure; Neutron Diffraction; Protein Binding; Protein Structure, Tertiary; Sulfonamides

2013
Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption.
    Drug metabolism and disposition: the biological fate of chemicals, 2013, Volume: 41, Issue:9

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biological Transport; Carbamates; Cytochrome P-450 CYP3A; Furans; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Mice; Permeability; Sulfonamides

2013
A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Journal of chemical information and modeling, 2013, Aug-26, Volume: 53, Issue:8

    Topics: Anti-HIV Agents; Carbamates; Cluster Analysis; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Indinavir; Molecular Dynamics Simulation; Mutation; Protein Conformation; Saquinavir; Sulfonamides; Thermodynamics

2013
In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
    Xenobiotica; the fate of foreign compounds in biological systems, 2014, Volume: 44, Issue:3

    Topics: Antirheumatic Agents; Atazanavir Sulfate; Bilirubin; Carbamates; Cyclosporine; Furans; Glucuronosyltransferase; HIV Protease Inhibitors; Hyperbilirubinemia; In Vitro Techniques; Indinavir; Liver-Specific Organic Anion Transporter 1; Oligopeptides; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyridines; Rifampin; Rifamycins; Saquinavir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides

2014
Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Cyclosporine; Digoxin; Dogs; Furans; Gene Expression; Humans; Ketoconazole; Kinetics; Loperamide; Madin Darby Canine Kidney Cells; Protein Binding; Quinidine; Sulfonamides; Tetrahydroisoquinolines; Vinblastine

2013
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
    Scientific reports, 2014, Nov-03, Volume: 4

    Topics: Carbamates; Catalytic Domain; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Binding; Protein Structure, Secondary; Sulfonamides; Thermodynamics

2014
Decoding the anti-Trypanosoma cruzi action of HIV peptidase inhibitors using epimastigotes as a model.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Animals; Anti-HIV Agents; Aspartic Acid Proteases; Carbamates; Furans; Host-Parasite Interactions; Indinavir; Insect Vectors; Lopinavir; Microscopy, Electron, Transmission; Nelfinavir; Protease Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Trypanocidal Agents; Trypanosoma cruzi

2014
A novel tricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor, GRL-0739, effectively inhibits the replication of multidrug-resistant HIV-1 variants and has a desirable central nervous system penetration property in vitro.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:5

    Topics: Blood-Brain Barrier; Carbamates; Darunavir; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Sulfonamides; Virus Replication

2015
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
    Scientific reports, 2015, May-27, Volume: 5

    Topics: Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Structure, Tertiary; Sulfonamides; Thermodynamics

2015
Understanding the basis of I50V-induced affinity decrease in HIV-1 protease via molecular dynamics simulations using polarized force field.
    Journal of computational chemistry, 2015, Sep-30, Volume: 36, Issue:25

    Topics: Carbamates; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Molecular Dynamics Simulation; Point Mutation; Protein Binding; Sulfonamides

2015
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.
    Journal of acquired immune deficiency syndromes (1999), 2015, Dec-15, Volume: 70, Issue:5

    Topics: Adult; Anti-HIV Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Sulfonamides; Viral Load

2015
Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
    Scientific reports, 2015, Aug-11, Volume: 5

    Topics: Carbamates; Darunavir; Fluorescence; Fluorescent Dyes; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Kinetics; Pyridines; Pyrones; Sulfonamides

2015
A Comparative Insight into Amprenavir Resistance of Mutations V32I, G48V, I50V, I54V, and I84V in HIV-1 Protease Based on Thermodynamic Integration and MM-PBSA Methods.
    Journal of chemical information and modeling, 2015, Sep-28, Volume: 55, Issue:9

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance, Viral; Furans; HIV-1; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Sulfonamides; Thermodynamics; Viral Proteins

2015
HIV protease inhibitors disrupt astrocytic glutamate transporter function and neurobehavioral performance.
    AIDS (London, England), 2016, Feb-20, Volume: 30, Issue:4

    Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Brain Chemistry; Carbamates; Cell Survival; Cells, Cultured; Female; Furans; Gene Expression Profiling; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Mice, Transgenic; Nervous System Diseases; Neurologic Examination; Sulfonamides

2016
Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.
    Drug delivery and translational research, 2016, Volume: 6, Issue:1

    Topics: Administration, Rectal; Animals; Caco-2 Cells; Carbamates; Cell-Penetrating Peptides; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Intestinal Mucosa; Male; Mice; Mice, Inbred Strains; Nanoconjugates; Peptides, Cyclic; Polyethylene Glycols; Pre-Exposure Prophylaxis; Sulfonamides

2016
Computational Prediction of HIV-1 Resistance to Protease Inhibitors.
    Journal of chemical information and modeling, 2016, 05-23, Volume: 56, Issue:5

    Topics: Amino Acid Sequence; Carbamates; Computational Biology; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Mutation; Protein Multimerization; Protein Structure, Quaternary; Sulfonamides

2016
A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:12

    Topics: Animals; Blood-Brain Barrier; Carbamates; Cell Line; Central Nervous System; Crystallography, X-Ray; Darunavir; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Viral; Ethylamines; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Peptides; Rats; Structure-Activity Relationship; Sulfonamides; Virus Replication

2016
Extrapolation of Elementary Rate Constants of P-glycoprotein-Mediated Transport from MDCKII-hMDR1-NKI to Caco-2 Cells.
    Drug metabolism and disposition: the biological fate of chemicals, 2017, Volume: 45, Issue:2

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Carbamates; Cell Culture Techniques; Cell Membrane; Cell Membrane Permeability; Digoxin; Dogs; Furans; Humans; Kinetics; Loperamide; Madin Darby Canine Kidney Cells; Models, Biological; Quinidine; Sulfonamides

2017
Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
    International journal of oncology, 2017, Volume: 50, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Breast Neoplasms; Carbamates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Repositioning; Female; Furans; HIV Protease Inhibitors; Humans; Male; MCF-7 Cells; Mice; Mice, Inbred C57BL; Mice, Nude; Mitogen-Activated Protein Kinase 1; Molecular Docking Simulation; Molecular Dynamics Simulation; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays

2017
Effects of Amprenavir on HIV-1 Maturation, Production and Infectivity Following Drug Withdrawal in Chronically-Infected Monocytes/Macrophages.
    Viruses, 2017, 09-28, Volume: 9, Issue:10

    Topics: Carbamates; Cells, Cultured; Furans; HIV Protease Inhibitors; HIV-1; Humans; Macrophages; Monocytes; Sulfonamides; Virus Replication

2017
Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet.
    Scientific reports, 2018, 01-15, Volume: 8, Issue:1

    Topics: Carbamates; Crystallography, X-Ray; Darunavir; Enzyme Inhibitors; Furans; HIV Protease; Protein Binding; Protein Conformation; Protein Subunits; Sulfonamides

2018
Exploring molecular mechanism of allosteric inhibitor to relieve drug resistance of multiple mutations in HIV-1 protease by enhanced conformational sampling.
    Proteins, 2018, Volume: 86, Issue:12

    Topics: Allosteric Regulation; Binding Sites; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Protease; HIV Protease Inhibitors; HIV-1; Hydrogen Bonding; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Sulfonamides; Thermodynamics

2018
Aspartic peptidase of
    Journal of enzyme inhibition and medicinal chemistry, 2020, Volume: 35, Issue:1

    Topics: Antifungal Agents; Aspartic Acid Proteases; Carbamates; Dose-Response Relationship, Drug; Furans; HIV Protease Inhibitors; Humans; Lopinavir; Macrophages; Microbial Sensitivity Tests; Molecular Structure; Phialophora; Ritonavir; Structure-Activity Relationship; Sulfonamides

2020
Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
    Physical chemistry chemical physics : PCCP, 2020, Feb-26, Volume: 22, Issue:8

    Topics: Anti-HIV Agents; Carbamates; Drug Resistance; Furans; HIV Protease; Indinavir; Molecular Conformation; Molecular Dynamics Simulation; Mutation; Nelfinavir; Protein Binding; Ritonavir; Sulfonamides

2020
Interactive molecular dynamics in virtual reality for accurate flexible protein-ligand docking.
    PloS one, 2020, Volume: 15, Issue:3

    Topics: Benzamidines; Binding Sites; Carbamates; Furans; HIV Protease; Ligands; Molecular Dynamics Simulation; Neuraminidase; Oseltamivir; Protein Binding; Sulfonamides; Trypsin; Virtual Reality; Zanamivir

2020
The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death.
    Parasitology international, 2021, Volume: 82

    Topics: Antiprotozoal Agents; Apoptosis; Carbamates; DNA Topoisomerases, Type I; Furans; HIV Protease Inhibitors; Leishmania donovani; Oxidative Stress; Protozoan Proteins; Sulfonamides

2021
Insights into effect of the Asp25/Asp25' protonation states on binding of inhibitors Amprenavir and MKP97 to HIV-1 protease using molecular dynamics simulations and MM-GBSA calculations.
    SAR and QSAR in environmental research, 2021, Volume: 32, Issue:8

    Topics: Aspartic Acid; Benzothiazoles; Carbamates; Furans; HIV Protease; HIV Protease Inhibitors; Molecular Dynamics Simulation; Protein Stability; Protons; Sulfonamides

2021